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ABSTRACT
DEVELOPMENT, EVALUATION AND APPLICATION OF INSULIN SOLUTION
AND FILM DOSAGE FORMS FOR SUBLINGUAL ADMINISTRATION
Anuja Paprikar
The major barrier for sublingual absorption of large molecules like insulin is low
permeability owing to the hydrophilic nature of insulin. One approach to overcome this
barrier is to sublingually co-administer insulin with permeation enhancers (HPβCD and
poloxamer 188). In vitro performance of permeation enhancers was screened across
cellulose acetate membrane to select the concentrations of both enhancers, which were
further evaluated across four models (MatTek tissue model, MDCK cell line, rat and
porcine esophagus). The insulin solution with combination of HPβCD (5%) and
poloxamer 188 (0.5%) indicates higher permeation as compared to that of only insulin
across all the four models. Subsequently, porcine esophagus was selected as a tool for in
vitro permeation studies for sublingual insulin solution. Furthermore, insulin-induced
hypoglycemic effect was observed for insulin solution formulations with combination of
HPβCD and poloxamer 188 after sublingual administration to Sprague-Dawley rats. An
increase in dose of insulin from 5, 10, and 15 IU/kg along with HPβCD and poloxamer
188, maximum reduction of glucose level increased. After exploring the feasibility of
HPβCD and poloxamer 188 for sublingual insulin solution administration, permeation of
insulin solution was optimized using three-level resolution III fractional factorial design.
In this design, the independent (X1: concentration of insulin; X2: concentration of
HPβCD; X3: concentration of poloxamer 188) and dependent (Y: cumulative amount
permeated at 60 minutes) variables were used. Based on the generated equation from this

design, not only contour and interaction plots were generated but also an optimized
formulation, and two checkpoint formulations were obtained to validate the design.
Thereafter, insulin at three doses for the optimized formulation and safety of permeation
enhancers was evaluated. Based on the optimized sublingual insulin solution, polymeric
sublingual films were formulated and evaluated. The sublingual insulin films were found
to have comparative mechanical properties to that of commercial film (Listerine®). Based
on in vitro dissolution and in vitro permeation, it can be concluded that the film on
dissolution could behave like insulin solution and hence is a feasible approach for
sublingual administration.
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1. Introduction
Diabetes mellitus is a medical condition wherein either the pancreas is unable to
produce insulin and/or use the available insulin for effective utilization of glucose for
automatic function. As per the National Diabetes Statistics Report, 2017, about 30.3
million people, which constitutes 9.4% of US population has diabetes (2). Currently,
injection of insulin or its analogues is the only treatment for insulin dependent diabetes
and reduces the patient compliance. Post discovery of insulin in 1921, non-invasive
administration for insulin has been studied. Among various approaches, oral
administration is the safest and most patient compliant. However, it involves major
hurdles like extensive degradation through gastrointestinal tract, lack of permeation
through epithelial cells, and first-pass effect in liver. To overcome these hurdles, oral
mucosal administration namely buccal and sublingual are hence considered valid
alternatives for drug administration.
Sublingual mucosa is highly vascularized and non-keratinized which allows rapid
absorption of the drug and can appear in the systemic circulation almost instantly. Hence,
drug administration via sublingual route helps not only to surpass gastrointestinal
degradation but also to avoid extensive first-pass effect. Bolus insulin is wherein the
insulin dose is to be taken at meal-times to keep blood glucose levels under control
following meals. In this case, sublingual insulin administration seems to be an attractive
option. Since there is a need for faster onset time, combination of using short-acting
insulin along with sublingual route could be a suitable approach. To date, very limited
research has been done on designing a sublingual film for protein molecules, such as

1

insulin. Therefore, this research project focuses on the development of sublingual film for
administration of insulin.
2. Literature review
2.1 Diabetes mellitus
Diabetes mellitus (DM) is seventh leading cause of death in the US. More than 29
million Americans are living with diabetes, and 86 million are living with prediabetes, a
serious health condition that increases a person’s risk of type 2 diabetes and other chronic
diseases. It is predicted that by 2050 as many as 1 in 3 US adults could have diabetes (3).
Diabetes mellitus is a disease caused by a deficiency of insulin in the body. There
are two distinct types of diabetes mellitus: type 1 or insulin-dependent diabetes (IDDM)
and type 2 or insulin-independent diabetes (NIDDM). A majority of the people with
diabetes in the US are affected by NIDDM. Both genetic and environmental factors
determine who may be affected by DM. In NIDDM, β-cells function normally, but the
body has a loss of sensitivity to the hormone. A positive family history is predictive for
developing NIDDM; some ethnic groups have a higher prevalence (e.g., American Indian,
African American, and Hispanic). Excess body weight, more than 20% of the normal, is
another risk factor. Previously identified impaired glucose tolerance, gestational diabetes,
hypertension or significant hyperlipidemias are also associated with increased risk of
developing NIDDM.
The diabetes control and complications trial established that prolonged exposure of
tissues to elevated blood glucose levels is the major factor leading to most complications
of DM (4). These complications include retinopathy, nephropathy, and neuropathy. More
importantly, cardiovascular and macrovascular complications may occur. The diabetes
2

control and complications trial have concluded that intensive and constant therapy
throughout 24 hours to control blood glucose levels in diabetes is essential to prevent
complications that make diabetes a debilitating disease. Insulin is an integral part of DM
therapy, as it acts to lower blood glucose levels by a number of mechanisms.
2.2 Current treatment strategies for diabetes mellitus
According to American Diabetes Association guidelines, type 2 diabetes care is
best provided by a multidisciplinary team of health professionals with expertise in diabetes,
working in collaboration with the patient and family. Management includes the following:
appropriate goal setting, dietary and exercise modifications, medications, appropriate selfmonitoring of blood glucose, regular monitoring for complications, laboratory assessment.
Ideally, blood glucose should be maintained at near-normal levels (preprandial levels of
90-130 mg/dL and hemoglobin A1C levels < 7%). However, focus on glucose alone does
not provide adequate treatment for patients with diabetes mellitus. Treatment involves
multiple goals (i.e., glycemia, lipids, and blood pressure, etc.).
Since insulin resistance is hypothesized to be a major factor in the development of
type 2 diabetes; treatment of resistance may prevent or delay the onset of diabetes.
Presently, the Diabetes Prevention Program is underway to ascertain which treatment for
insulin resistance may help prevent or delay the onset of diabetes. These treatments include
intensive lifestyle changes (7% reduction of body weight through caloric restriction and
exercise) and use of metformin (5).
Insulin is the mainstay for treatment of virtually all type 1 and 2 diabetes patients.
The main goal of insulin replacement therapy in diabetes mellitus is to reproduce or mimic
this endogenous pattern of insulin secretion as close as possible. The current treatment
3

strategy of Diabetes Mellitus combines several short acting insulins (meal-time insulin)
with one or two long acting insulin (basal insulin), such as Lantus (isoelectric modified
insulin) or Detemir (acylated insulin), to obtain the total daily insulin requirement. During
the initial stages of diabetes, the patients are started on oral hypoglycemic agents. However,
the need for insulin therapy still exists since eventually use of insulin becomes a
requirement. At diagnosis, a patient with type 2 diabetes has only 50% of β-cell function
remaining. Given this inevitable decline in β-cell function and insulin secretion, most
patients with type 2 diabetes will require insulin therapy at some point.
2.2.1 Insulin
Insulin was discovered by Sir Frederick Grant Banting and Charles Herbert Best,
in 1921, when it was extracted from the pancreatic tissue of dogs. Galloway and Chance
reviewed the history of the development of the different preparations and the problems of
current insulin treatment (6). The goal of insulin therapy is to normalize not only the blood
glucose levels but also all aspects of metabolism. In general, therapy aims to maintain
fasting blood glucose levels between 90-120 mg/dL and a two hours postprandial level
below 150 mg/dL.
The current insulin replacement therapy in diabetic patients combines basal insulin
with bolus insulin; this strategy, however, requires multiple short or rapid- acting insulin
injections to mimic the bolus supply and one or two intermediate or long-acting insulin
injections to mimic the endogenous basal insulin, in various combinations and doses to
meet patient’s needs. Such a dosage regimen is obviously painful and cumbersome to the
patients. Diabetic patients suffer from various problems, such as physical and psychic pain,
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hypertrophy or atrophy of the subcutaneous fat at an injection site. Hence, there is a need
for a more patient compliant form of insulin administration.
2.2.1.1 Structure and conformation
Proinsulin is a single polypeptide chain of 86 amino acids that permit correct
alignment of three pairs of disulfide bonds. Insulin is derived from proinsulin by cleavage
of the C-peptide structure at the dipeptides Arg-Arg and Lys-Arg. Insulin is composed of
an A chain of 21 amino acids and a B chain of 30 amino acids, the chains being held
together by disulfide bonds. A third disulfide bond is present within the A chain. The A
chain forms two antiparallel alpha helices (A2-A8 and A13-A20), while the B chain forms
a single alpha-helix (B9-B19), followed by a turn and a β-strand (B21 and B30). The
arrangement of A and B chains buries the cysteine residues at A6 and A11 positions and
the aliphatic side chains of residues at A2, A16, B11, and B15 in the non-polar core. The
surface of insulin monomer is thus covered with both polar and non-polar residues (7).
The steric structure is determined by the positions of the disulfide bridges and is
dependent on the Vander Waal’s forces between them. Conformational-activity studies
have demonstrated that a certain steric structure is required for biological activity (8, 9).
Insulin is catabolized mainly in the liver and kidneys. An insulin-specific protease and
glutathione-insulin transhydrogenase are involved. The latter reduces the disulfide bonds
with separation of A and B chains, which are subjected to rapid proteolysis.
Insulin is synthesized in the beta cells of the pancreatic islets of Langerhans. The
secretion of insulin is controlled by the concentration of glucose in the bloodstream. Insulin
concentration in the plasma increases with the increase in glucose concentration in the
blood, which usually follows eating a meal. Insulin plays a major part in the uptake of
5

glucose by the cells of the body. The secretion of insulin also stimulates the formation of
glycogen in the liver, while suppressing gluconeogenesis by the liver and facilitating the
synthesis of fatty acids. Insulin also controls the uptake of valine, leucine and isoleucine
by the muscles, which in turn helps to increase the synthesis of muscle proteins (10).
2.2.1.2 Stability of insulin
Pure insulin is very stable and retains biological activities for long periods of time
in sterile solution at 2°C and loses about 20% of its biological activity after one year at 2025°C (11).
Degradation of insulin occurs by both physicochemical and enzymatic action on
the molecule. In dilute acids, hydrolysis occurs preferentially at the Asn and Gln residues,
while in alkaline solutions, amide linkages and cysteine residues are rapidly hydrolyzed.
The primary β-amide group in the C-terminal Asn residue at A21 is most sensitive to
hydrolysis; this de amido-insulin, however, retains its biological activity (12, 13).
The three disulfide bridges are essential for activity and cleavage of any one of
them could result in loss of biological activity. Reduction of the disulfide bridges occurs
slowly in acidic media and rapidly in alkaline media. It is further accelerated in the presence
of alcohol and heavy metal ions (14). The two interchain disulfide bridges are believed to
be more susceptible to reduction than the intrachain bridge in the A-chain (15).
A number of enzymes are involved in the degradation of insulin. Metal-free insulin
is more rapidly cleaved by proteases. While the native insulin is rather resistant to
enzymatic action once one bond has been cleaved by leucine-aminopeptidase, trypsin, or
chymotrypsin, its remaining breakdown by other enzymes progresses rapidly (16, 17).
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Leucine aminopeptidase rapidly breaks down the B chain at the lipophilic Nterminal (B1-B6), which is not required for activity (18). Carboxypeptidase A cleaves the
C-terminals of both the A and B chains, resulting in loss of biological activity. Cleavage
of the B22-B23 and B29-B30 bonds by trypsin results in an inactive insulin molecule (19,
20). Enzymatic reduction of the disulfide bridges is believed to be the first step in in vivo
degradation of insulin (21).
2.3 Oral mucosal administration of insulin
Several experimental approaches to optimize insulin therapy are currently being
investigated. These include the use of insulin analogues, new routes of administration,
intraperitoneal devices, implantable pellets, closed-loop artificial pancreas, islet cells and
pancreas transplantation, and gene therapy. Exubera was approved by the US Food and
Drug Administration in January 2006. Upon approval, Pfizer and market analysts predicted
that Exubera would be a blockbuster drug since it was the first inhaled option for people
who needed to take insulin. However, Exubera’s high price and bulky inhaler, as well as
concerns about its effects on lung function, led to much lower sales than had been expected.
Also, because Exubera was not shown to control blood glucose levels any better than
already-existing treatments, insurance companies were reluctant to cover it. In the end,
Exubera captured less than 1% of the insulin market. Hence, in October 2007, Exubera was
taken off the market. In 2014, after several efforts at developing “ultra-rapid” insulins had
been undertaken, and one such product, Afrezza (insulin human; Inhalation Powder,
MannKind Corporation, Danbury, CT) has been approved by the US FDA. Even though
inhalable insulin has been approved, it still lacks patient compliance. With the use of oral
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mucosal administration, more patient compliant dosage form like fast-disintegrating film
for meal-time insulin seems an attractive option.
The oral cavity is an attractive site for the administration of drugs either locally or
directly into systemic circulation. Its attractiveness resides in the fact that the mucosal
membranes, upon which drug delivery systems are located, are readily accessible to
patients. This means that the administration technology can be precisely placed on the
specific oral cavity membrane that is chosen as the site of absorption. It also means that
the dosage form can be removed in order to terminate delivery if signs of adverse reactions
are observed during treatment. The oral cavity represents a challenging area to develop
effective administration technology. This arises due to the various inherent functions of the
oral cavity (eating, swallowing, speaking, chewing, etc.), as well as the presence of the
fluid that is involved in all these activities, saliva. This fluid is continually secreted into
and then removed from the mouth. There are many advantages and disadvantages
associated with the oral cavity as a site for drug administration. Overall, however, it
remains a viable option as a route for drug administration and has been extensively studied
for that purpose (22).
Ultimately, the decision to utilize the oral cavity as a site for drug administration
should be based on a comparison to other sites of administration about the following
parameters: the clinical objectives of the treatment, the inherent physicochemical
properties of the drug, the relative advantages of the route, product differentiation
opportunities, the patient population and the cost of development and production.
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2.3.1 Considerations in product development
2.3.1.1 Drug absorption across the oral mucosa
Two major routes of absorption are involved in oral mucosal drug permeation: the
transcellular or intracellular route (where drugs permeate directly through the cells) and
the paracellular or intercellular route (where drugs permeate by passive diffusion through
the spaces between the cells). The paracellular route is favored, especially by hydrophilic
drugs, as well as peptides/proteins, which dissolve more readily in the aqueous fluids filling
the intercellular spaces (22).
2.3.1.2 Influence of physiological and anatomical features of the oral cavity
Saliva constitutes an important physiological feature of oral cavity, which
influences dissolution of drug. It continuously bathes the surface of the oral mucosa and
maintains a moist, stable environment. It is a relatively mobile fluid compared to the
secretions of the gastrointestinal tract and contains less mucin, limited enzymatic activity,
and virtually no proteases. Saliva has a slightly acidic pH, which is favorable for a wide
range of drugs, and it can be modified easily at the site of administration. Although it has
a relatively small surface area as compared to other absorption sites of the body, it is
generally sufficient to allow for absorption of drugs with appropriate physicochemical
properties.
Keratinized mucosa usually located in regions of the mouth that do not flex (gum
and palate), provides an additional barrier to drug absorption. Non-keratinized mucosa is
more permeable than keratinized mucosa (buccal and sublingual) and tends to be in regions
of the mouth that are flexible.
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Sublingual mucosa is relatively thin as shown in Figure 1. Therefore, this region is
good for rapid drug absorption. Buccal mucosa is relatively thick and absorption may be
too slow to be useful for bolus drug administration. Also, biochemical composition of
sublingual mucosa favors the permeation of hydrophilic compounds. This is because of
presence of polar lipids in the sublingual mucosa, which lead to increased fluidity of the
membrane and higher permeation of water and other hydrophilic compounds (1). Buccal
and sublingual mucosa contain less enzymes as compared to other mucosae like nasal,
rectal, and vaginal. Moreover, oral cavity enables a way to deliver solid dosage forms such
as a film more easily as compared to nasal mucosa. Since the objective of this study is to
deliver bolus insulin, sublingual route will be considered.
2.3.1.3 Influence of drug properties
The physicochemical properties of the drug play a crucial role in the design and
formulation of an oral mucosal drug dosage form. It is of utmost importance that the
physicochemical properties of the drug are characterized in order to allow for initial
selection and subsequent formulation into an oral mucosal drug dosage form. The desirable
drug physicochemical properties for formulation of an oral mucosal drug dosage form are
as follows: good aqueous solubility, log P in between 3 to 6, molecular weight < 500 Da,
pH of saturated aqueous solution (pH 5–9), required dose deliverable < 10 mg/day, and no
irritation to buccal/sublingual tissue.
2.3.1.4 Development of sublingual insulin solution and film dosage forms
Very limited research has been reported on sublingual administration of insulin.
Coupling insulin with permeation enhancers showed a decrease in blood glucose levels
(23). The enhancing effects of using permeation enhancers may be due to one or multiple
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factors: increasing the mucosal lipid ﬂuidity, directly loosening of the tight junction of
epithelia, and dissociating the hexamers of insulin to monomers. The attempt to deliver
insulin sublingually in form of bioadhesive nanoparticles using nicotinamide as a natural
permeation enhancer has been reported (24). Furthermore, sublingual administration in the
form of orally disintegrating film for meal-time insulin seems an attractive option. As of
now, there is no such dosage form available in the market for insulin. Since evaluation of
film in vivo is not feasible due to smaller oral cavity of rats, sublingual insulin solution
dosage form was developed and evaluated first. Based on the outcomes obtained from
development of sublingual insulin solution dosage form, sublingual insulin film dosage
form was further developed.
The major barrier for sublingual absorption of large molecules like insulin is low
permeability owing to the hydrophilic nature of insulin. Various strategies to improve
permeability include the use of permeation enhancers and/or addition of enzyme inhibitors
to increase their stability, modification with bioreversible chemical groups or specific
formulations like bioadhesive delivery systems. The passage of insulin across sublingual
mucosa through the paracellular pathway is restricted by the mucosal tight junction. One
approach to overcome this barrier is to sublingually co-administer insulin with permeation
enhancers (25, 26).
Permeation enhancers, such as hydroxypropyl beta-cyclodextrin (HPβCD),
chitosan,

polyethylene-polypropylene

glycol

(poloxamer

188),

polysorbate

80,

polyoxyethylene lauryl ether, egg lecithin, and oleic acid, have been used to significantly
increase hypoglycemic activity of insulin in normal rats (23). The use of HPβCD has been
reported to be an effective permeation enhancer for many lipophilic and hydrophilic drugs.
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In addition, it has shown a promising effect on absorption of drugs like insulin, acyclovir,
and calcitonin having low permeability (27-29). Therefore, HPβCD was selected as a
permeation enhancer in this investigation. Moreover, although poloxamer 188 has been
explored as a permeation enhancer for lipophilic drugs, such as fexofenadine and
isosorbide dinitrate, so far, very limited information is available regarding its permeation
enhancement for hydrophilic drugs (30, 31). Till now, there has been a single report, which
has stated the promising use of poloxamer 188 as a permeation enhancer for hydrophilic
drug (i.e., sumatriptan succinate) (32). Hence, poloxamer 188 was selected and evaluated
as another permeation enhancer in this investigation. Moreover, it can be expected that the
permeation enhancers, when given in combination, will work better owing to a slightly
different mechanism of action(s).
In order to evaluate sublingual in vitro performance of the permeation enhancers, a
proper in vitro model needs to be selected. It could be noted that artificial membranes like
cellulose acetate, cellulose nitrate, polypropylene, polyethersulfone, and dialysis
membranes have been employed to evaluate oral mucosal formulations wherein the main
mechanism of absorption is passive diffusion (33). In this investigation, to study effect of
concentration of permeation enhancers, artificial membranes like cellulose acetate could
be employed. In addition, tissue model, cell lines, or animal tissues could be employed as
biological membranes as well.
Out of the available tissue models, EpiOral™ tissue model consists of normal,
human-derived oral epithelial cells. The cells are cultured to form multilayered, highly
differentiated models of the human buccal (EpiOral™) phenotypes. The EpiOral™ tissue
model exhibits in vivo-like morphological and growth characteristics. Moreover, the
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histology of EpiOral™ is such that 8-11 cell layers of non-cornified tissue could be
cultured, enabling it to be physiologically relevant (34). In comparison with other in vitro
human buccal mucosa models, it has been described as being the histologically closest to
human buccal mucosa (34, 35).
In absence of a relevant tissue model for sublingual mucosa, the next choice for in
vitro permeation studies could be a cell line that consists of monolayer, unlike the tissue
model which is not cost efficient. Although the use of Caco-2 cell line is widely accepted
tool for assessing permeability, due to its 3-week growth period, new alternatives have
been considered (36). It has been reported that MDCK cells have shown similar
permeability data as Caco-2 cells, for passively absorbed compounds (37). Hence, under
the assumption that insulin is absorbed by passive diffusion, the MDCK cell line was used
to evaluate the sublingual insulin formulations.
However, to evaluate the effectiveness of permeation enhancers, the use of
biological membranes like buccal or sublingual tissue could be employed as well.
Nevertheless, very limited literature is available for in vitro drug transport studies across
sublingual unlike across buccal mucosa, which is closely related to sublingual mucosa.
Hence, the models available for in vitro performance across buccal mucosa may be
evaluated for sublingual mucosa as well. The rodent tissue is readily available; however,
the epithelium is very thick and keratinized, and the surface area is small. Dog mucosa is
non-keratinized and similar to humans, but its routine use for in vitro experiments is
expensive. On the other hand, porcine buccal mucosa is non-keratinized and is closest to
human tissue in terms of structure and permeability. While its availability and low cost
make it a good model for experiments, cheek surface is small, and a regular supply of fresh
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tissue undamaged by mastication cannot be guaranteed. Furthermore, the mucosa is ﬁrmly
attached to the underlying muscular tissue; thus, its excision is fastidious and timeconsuming. To overcome these drawbacks, replacement of buccal mucosa by the porcine
esophageal mucosa has been proposed. The latter offers a larger, and typically intact,
surface area, and like buccal tissue, the esophagus consists of a stratiﬁed, squamous, nonkeratinized epithelium supported on a connective-tissue layer. Based on the anatomical
similarity, feasibility, and cost-effectiveness, in the current study porcine esophagus has
been explored as an alternative sublingual mucosa to study in vitro performance of insulin
in terms of permeation. In this study, based on the availability, both rat and porcine
esophagus were considered to evaluate permeation of insulin in presence of permeation
enhancers.
As discussed previously, despite the various advantages of sublingual
administration, number of drugs developed is very limited. One of the reasons is lack of a
simple and reliable model for in vitro assessment. Hence, the current study is focused upon
evaluation of in vitro performance of sublingual insulin formulations across various
models. Also, the evaluated permeation enhancers were investigated for their effectiveness
in Sprague-Dawley rats. Thus, after exploring the feasibility of permeation enhancers (i.e.,
HPβCD and poloxamer 188) for sublingual insulin administration, permeation of insulin
was optimized using design of experiments approach.
A response surface design is a set of advanced design of experiments
techniques that help to optimize the response. A three-level resolution III fractional
factorial design was employed in this investigation to optimize the insulin permeation using
response surface methodology statistically. As compared to full factorial design, fractional
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factorial provides an advantage of less number of runs. Considering all above-mentioned
facts for the current study, fractional factorial design was applied to optimize insulin
permeation. Thereafter, the optimized sublingual insulin solution formulation was
evaluated in vivo at various doses. In addition, the safety of permeation enhancers was also
evaluated. After preliminary screening studies, polymeric sublingual films were
formulated and evaluated based on the optimized sublingual insulin solution formulation.
3. Research objective and specific aims
The primary objective of this research is to formulate and evaluate solution and
film dosage forms for sublingual insulin administration.
Specific aims include:
Aim 1: Development of sublingual insulin solution dosage form
i. To screen the concentration of HPβCD and poloxamer 188 across cellulose acetate
membrane in order to formulate insulin solution dosage form, and to evaluate in vitro
performance of sublingual insulin solution using MatTek tissue model, MDCK cell line,
rat esophagus, and porcine esophagus
ii. To evaluate in vivo performance of sublingual insulin solution with and without
combination of HPβCD and poloxamer 188 using rat as an animal model
iii. To apply design of experiments across porcine esophagus to in vitro permeation of
sublingual insulin solution, to evaluate in vivo performance of optimized sublingual insulin
using rat as an animal model, and to evaluate safety of permeation enhancers in the
optimized sublingual insulin solution
Aim 2: Development of sublingual insulin film dosage form based on the optimized
solution dosage form
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i.To formulate PVA based sublingual insulin films and to study effect of PVA concentration,
insulin concentration, and type of plasticizer on thickness, drug loading, and disintegration
time of films
ii.To formulate sublingual insulin film using previously optimized concentrations of HPβCD
and poloxamer 188 obtained from solution dosage form, and to additionally characterize
the sublingual insulin film for its mechanical properties
iii.To formulate sublingual insulin film in order to increase insulin content, to characterize the
sublingual insulin film for thickness, insulin content, disintegration time, mechanical
properties, in vitro dissolution, and in vitro permeation studies, and to evaluate the stability
of the optimized sublingual insulin film dosage form
4. Materials and methods
4.1. Materials
Insulin (human recombinant), (2-hydroxypropyl)-β-cyclodextrin, triethylamine,
phosphoric acid, acetonitrile, and PEG 400 were purchased from Sigma Chemicals (St.
Louis, MO). Poloxamer 188 was purchased from Alfa Aesar (Ward Hill, MA).
Parteck®MXP (polyvinyl alcohol) and Parteck®SI 150 (sorbitol) were generously gifted
by EMD Millipore Sigma (Burlington, MA). Glycerin was purchased from VWR
Chemicals BDH® (Solon, OH). All other chemicals of analytical grade were used as
received.
4.2 Analysis of insulin
The insulin content of samples obtained from in vitro performance studies was
determined using HPLC system (Agilent Technologies Inc., Santa Clara, CA) equipped
with a HP1100 quaternary pump, auto-sampler and a UV detector, a µBondapak C18
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column, 2.1 × 300 mm, 10 µm (Waters, Milford, MA). Separation of insulin from samples
was achieved by isocratic conditions with a flow rate of 1.0 ml/min using reported method
with slight modification in mobile phase to avoid interference by solvents (38). The mobile
phase was composed of 1% triethylamine in Nanopure® water and acetonitrile (70:30 v/v)
adjusted to pH 2.5 using phosphoric acid. The injection volume was 20 µl. The areas under
the peak were used to calculate the respective concentrations of insulin and establish their
linearity as represented in Figure 2.
For in vivo performance studies, human insulin ELISA kit by Crystal Chem Inc.
(Elk Grove Village, IL) was used to quantitate human insulin in rat serum samples. All
procedures were followed as per the instruction manual provided by the company. The
colorimetric endpoint of the assay was determined at 450 nm by a microplate reader
spectrophotometer.
4.3 Development of sublingual insulin solution dosage form
To develop insulin in solution dosage form, the major issue is with absorption of
insulin due to its low permeability across oral mucosa. Hence, the critical factors affecting
insulin permeability, like type and concentration of permeation enhancers, were
investigated. In order to do so, due to unavailability of an established tool for in vitro
evaluation of sublingual dosage forms, a suitable in vitro tool was explored. Further, after
evaluating type and concentration of permeation enhancers, the combination of permeation
enhancers was evaluated across various in vitro tools. These sublingual insulin
formulations were then evaluated for the hypoglycemic activity at various doses along with
permeation enhancers in Sprague-Dawley (SD) rats. Based on this, the permeation of
insulin was optimized in terms of the critical factors affecting insulin permeability (i.e.,
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concentration of insulin and concentration of permeation enhancers) using design of
experiments approach. Finally, the optimized formulation was evaluated in vivo for the
hypoglycemic activity. In this way, sublingual insulin solution dosage form was developed,
which could be further used to develop film dosage form.
4.3.1 Preparation of sublingual insulin solution formulations
Appropriate amount of insulin was dissolved in 0.1N hydrochloric acid, followed
by adjusting pH to 6.8 using sodium hydroxide for preparing insulin concentration at 1
mg/ml (i.e., 30 IU/ml). HPβCD (10% w/v) and poloxamer 188 (2% w/v) were prepared in
pH 6.8 buffer, respectively. Aliquots of insulin solution (30 IU/ml), HPβCD (10% w/v),
and poloxamer 188 (2% w/v) were mixed to achieve various sublingual insulin
formulations subjected to following in vitro and in vivo evaluations.
4.3.2 Experimental set up for in vitro permeation studies
The in vitro performance of the sublingual insulin formulations was evaluated via
in vitro permeation studies using cellulose acetate membrane followed by Mattek tissue
model, MDCK (Madin−Darby canine kidney) cell line, rat and porcine esophagus.
Cellulose acetate membrane (with a pore size of 0.45 µm) was used as an artificial
membrane for permeation studies to screen the suitable concentration of permeation
enhancers. The in vitro permeation studies were carried out using side-by-side permeation
cells (PermeGear, Hellerton, PA) with a permeation surface area of 0.64 cm2 and a capacity
of 3.5 ml for the donor and the receptor compartments. The cellulose acetate membrane
was sandwiched between the two compartments. Each sublingual insulin formulation
consisted of insulin at 10 IU/ml with or without the permeation enhancer (i.e., HPβCD or
poloxamer 188 both at various concentration levels, respectively). The formulation was
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placed in the donor compartment, while phosphate buffer saline (PBS) was placed in
receptor compartment. The temperature was maintained at 37 ± 0.5°C by circulating water
jackets (VWR International, Aurora, CO). Samples (200 µl each) were withdrawn from the
receptor compartment at 15, 30, 45, 60, 75, and 90 minutes and replaced by an equal
volume of fresh PBS. The insulin content of the withdrawn samples was determined by the
HPLC or ELISA, as described above. Each formulation was tested in triplicate.

4.3.2.1 MatTek tissue model
Upon identifying the suitable concentration of permeation enhancers, permeation
effects of the combination of HPβCD and poloxamer 188, on insulin were further evaluated
using MatTek tissue model. The twelve EpiOral™ tissues and assay medium were used as
received from MatTek. In this study, four tissues were used at a time. The sublingual insulin
formulations were evaluated as per the protocol provided by the manufacturer.
In brief, the 24-well plates were labeled to accommodate four tissues to be
measured at five time points. The first well was labeled as 1-hour equilibration, followed
by the remaining wells as 0.5, 1.0, 1.5, 2.0, and 2.5 hours, respectively. The tissues were
then removed from the refrigerator (which were placed as and when received) and then
transferred aseptically in wells labeled 1-hour equilibration containing pre-warmed assay
medium. Further, the tissues were equilibrated with assay medium for one hour at 37 ±
0.5°C, 5% CO2. Following the 1-hour equilibration, the cell culture inserts were moved to
0.5 hour labeled wells, and 0.3 ml of donor solution was pipetted onto the tissue. The plates
were then returned to the incubator. After 30 minutes of elapsed permeation time, the
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tissues were moved to 1-hour wells. Similarly, the tissues were moved after 1.5, 2.0, and
2.5 hours of total elapsed time, each containing pre-warmed receiver assay medium. At the
end of experiment, all the wells containing receiver assay medium were analyzed for
insulin content using ELISA.
4.3.2.2 MDCK cell line
In this study, MDCK (Madin−Darby canine kidney) cells were investigated as a
possible tool for assessing the in vitro permeation studies for sublingual mucosa. In brief,
MDCK cells were seeded onto the polyester membranes of the transwells inserted on the
6-well plate at a density of 65000 cells/cm2 while the donor compartment of the 6-well
plate contained 1.5 ml cell suspension and 2.5 ml media in the receptor compartment.
The plate was incubated under 5% CO2 in humidified air at 37 ± 0.5°C for 24 hours to
allow the attachment. The medium was replaced on third day after seeding the plate and
every day after that till the transport study was performed. On the day of the experiment,
the MDCK cells monolayer was washed by Dulbecco’s phosphate buffer saline (DPBS),
and 1.5 ml DPBS was added to the donor compartment and 2.5 ml DPBS to the receiver
compartment following which the TEER was measured. At the beginning of this
experiment, DPBS was withdrawn from the donor compartment and replaced by the same
volume of FITC-INS solution with and without the permeation enhancers. The whole
system was set under 37 ± 0.5°C, and 1 ml of the solution was aliquoted from the
receiver compartment at predetermined time points and analyzed by fluorescence
spectroscopy (EX = 475 nm, EM = 550 nm) to determine the concentrations of FITC-INS
solution with and without the permeation enhancers.
4.3.2.3 Rat esophagus
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Upon identifying the suitable concentration of permeation enhancers, permeation
effects of the combination of HPβCD and poloxamer 188, on insulin were further
evaluated using rat esophagus (excised after euthanizing rats used in this study) as a
biological membrane. The esophagus was rinsed with DPBS prior to conducting in vitro
permeation studies and then mounted on to the donor compartment of the permeation
cells, with the mucosal side facing the donor compartment. Thereafter, the in vitro
permeation studies were carried out similarly as described previously.
4.3.2.4 Porcine esophagus
The permeation effects of the combination of HPβCD and poloxamer 188 on
insulin were further evaluated using porcine esophagus (Lampire Biologicals
Laboratories, Pipersville, PA) as a biological membrane, upon identifying the suitable
concentration of permeation enhancers. The frozen samples of porcine esophagus were
thawed at room temperature and rinsed with DPBS prior to conducting in vitro
permeation studies. The epithelium (with a thickness of 600-800 µm) was separated from
the underlying connective tissues with surgical scissors and mounted on to the donor
compartment of the permeation cells, with the mucosal side facing the donor
compartment. Thereafter, the in vitro permeation studies were carried out similarly as
described previously.
Further, all the four models were assessed for their suitability as a potential tool
for in vitro sublingual permeation studies, based on the results of the permeation studies,
feasibility and physiological relevance.
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4.3.3 Experimental set up for in vivo studies
The in vivo studies of insulin were performed using Sprague-Dawley (SD) rats (56 weeks, 200-225 g) purchased from Taconic Biosciences (Germantown, NY). All
experiments were conducted as per approved protocol by Institutional Animal Care and
Use Committee. The weight of rats was measured and recorded before start of each
experiment. To ensure complete sublingual dosing, rats were anesthetized in an
isoflurane chamber initially at 3% of isoflurane, followed by placing the rats comfortably
in a prone position and maintaining isoflurane at 1% throughout the study period.
Furthermore, each group of six rats received insulin sublingually. After application of
local anesthetic (lidocaine) to the tail, it was clipped off (1-2 mm of tail tip) with surgical
blade for blood collections. The blood glucose levels were measured at -20, -15, -10, -5
(pre-dosing), 5, 15, 30, 45, 60, 75, 90, 120, 150, 180, and 210 minutes, respectively,
using commercially available Accucheck® Aviva® blood glucose monitoring system. In
addition to blood glucose measurements, the serum insulin levels were measured. The
blood samples (150 µl each) were collected from the tail vein using tail-tipping method at
-20 (pre-dosing), 10, 20, 30, 45, 60, 90, and 180 minutes, respectively, and placed in
serum separating tubes, followed by separation of serum by centrifugation at 4000 rpm
for 15 minutes. Gentle massage was applied to facilitate blood collection from the tail at
each time point. Serum insulin levels were determined using human insulin ELISA kit
Crystal Chem Inc. (Elk Grove village, IL). At the end of the experiments, the rats were
euthanized by carbon dioxide asphyxiation.
For the pharmacodynamic profiles to be plotted as percentage change of blood
glucose levels, the mean of four pre-dosing (-20, -15, -10 and -5 minutes) blood glucose
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levels were noted as the basal blood glucose level and was further expressed as
percentage of the basal blood glucose level. In addition, values of minimum glucose
concentration, time to minimum glucose concentration, and maximum decrease in
glucose level were obtained from pharmacodynamic profiles and used for statistical
analysis. On the other hand, pharmacokinetic parameters of serum insulin concentrationtime curves, such as peak insulin concentration, the time to reach the serum peak level,
and mean residence time, were determined by non-compartmental analysis using
WinNonlin® (Pharsight, Cary, NC). In addition, the basal endogenous insulin level was
subtracted from all insulin levels measured following insulin administration to normalize
the serum insulin concentrations.
4.3.3.1 Evaluation of dosages for sublingual insulin formulations
Each group of six rats received insulin sublingually at the dose of 5, 10, and 15
IU/kg, respectively, along with selected concentration of permeation enhancers based on
in vitro permeation studies. To serve as control groups, sublingual saline and
subcutaneous insulin solution (1 IU/kg), respectively, were administered to rats.
4.3.3.2 Effect of permeation enhancers
In addition to the detailed procedure as outlined previously, to evaluate effect of
permeation enhancers, each group of six rats received insulin sublingually at the dose of
15 IU/kg, along with selected concentration of permeation enhancers based on in vitro
permeation studies. To serve as control groups, sublingual saline, insulin solutions (15
IU/kg), subcutaneous insulin solution (1 IU/kg), and only permeation enhancers,
respectively, were administered to rats.
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4.3.4 Application of design of experiments
The techniques for the optimization of pharmaceutical products by means of
statistical experimental design methodologies have been successfully applied for various
sublingual, buccal, and transdermal formulations (39-41). In addition, these techniques
optimize not only critical formulation components but also their concentrations. For
instance, using design of experiments approach, fractional factorial design was applied in
the preparation of transdermal films to select the optimum formulation constituents and
their concentrations (42). Moreover, it has also been reported that different enhancers,
which have shown synergistic effects, have been employed simultaneously in
optimization process as well (43). Based on this, after evaluating synergistic effect of
HPβCD and poloxamer 188, in the current investigation, a three-level resolution III
fractional factorial design was employed to statistically optimize the insulin permeation.
4.3.4.1 Optimization of concentration of insulin and permeation enhancers across porcine
esophagus
The in vitro permeation studies were carried out using side-by-side permeation
cells (Perme Gear, Hellerton, PA) as outlined in detail in the previous section. Briefly,
after rinsing the porcine esophagus with Dulbecco’s phosphate buffer saline (PBS), the
epithelium (with a thickness of 600-800 µm) was separated from the underlying
connective tissues with surgical scissors and mounted on to the donor compartment of the
permeation cells, with the mucosal side facing the donor compartment. Each formulation
consisted of insulin with or without the permeation enhancers (e.g., 5% HPβCD and 0.5%
poloxamer 188) was placed in donor compartment, while PBS was placed in receptor
compartment. The temperature was maintained at 37 ± 0.5°C by circulating water jackets
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(VWR International, Aurora, CO). Samples (200 µl each) were withdrawn from the
receptor compartment at 0, 15, 30, 45, 60, 75, and 90 minutes and replaced by an equal
volume of fresh PBS solution. The insulin content of the withdrawn samples was
determined by HPLC analytical method. Each formulation was tested in triplicate.
A three-level resolution III fractional factorial design was employed in this
investigation to optimize the insulin permeation statistically. Based on the literature and
preliminary experiments (explained in previous sections), concentration of insulin (5-15
IU/ml), concentration of HPβCD (0-10 %), and concentration of poloxamer 188 (0-1%)
were selected as independent variables while cumulative amount permeated at 60 minutes
(IU/cm2) was evaluated as a dependent variable (response). Based on these, the statistical
design was generated as outlined in Table 2. Further, the ten runs generated by Fusion
Pro software (S-Matrix Corporation, Eureka, CA) were subjected to in vitro permeation
evaluation (Table 3).
For statistical analysis of the experimental design, a quadratic model of
cumulative amount permeated at 60 minutes (Y) as a function of independent variables
(X1, X2, X3) can be represented as Y= (X1, X2, X3). Y was further analyzed by multiple
regressions through the least-squares method to fit the following polynomial equation 1:
Y = b0 + b1 X 1 + b2 X 2 +b 3 X 3+b12 X 1 X 2 + b13 X 1 X 3 + b23 X 2 X 3 + b11 X 12 + b22 X 22 + b33 X 32

Equation 1

Where Y is cumulative amount permeated at 60 minutes; b1 to b33 are the
regression coefficients computed from the observed values of Y; and X1, X2, and X3 are
the coded levels of independent variables. The terms XiXj (i, j=1,2, or 3) and Xi2 (i=1,2,
or 3) representing the interaction and quadratic terms, respectively, are used to simulate
the curvature of the design space. The selection of polynomial equation for analyzing the
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response variable was made based on coefficient of determination (R2) between 0.7 and 1
and lower standard deviation. Equation 1 can be represented in the form of coded
variables as well as natural variables. Although the coded variables equation is used to
evaluate relative impact of independent variables, generation of contour, and interaction
plots is based on natural variables equation.
In this study, the contour plots were used to evaluate effect of concentration of
HPβCD, concentration of poloxamer 188 on insulin permeation at the three levels of
insulin. Also, interaction plots were generated to study the interaction between the
independent variables. Furthermore, three checkpoint formulations were generated for the
validation of prediction accuracy of the generated model (Table 4). The checkpoint
formulations were evaluated for the response variable, and the resultant observed values
were quantitatively compared with the predicted values. Thus, this technique can be used
to obtain a model that helps not only to understand the effects of the independent
variables and their levels over the whole experimental design space but also to predict the
response within this design space. Moreover, it can be used for optimizing a response,
carrying out simulations with the model equation, and plotting the responses.
Upon conducting the design of experiments to optimize the concentrations of
permeation enhancers, the sublingual insulin formulation was further evaluated for in
vivo performance.
4.3.4.2 In vivo evaluation of optimized sublingual insulin formulations
The in vivo studies were carried out as mentioned in above section. Furthermore,
each group of three rats received insulin sublingually at three different doses,
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respectively, along with optimized concentration of permeation enhancers based on
design of experiments.
4.3.4.3 Safety of permeation enhancers
The porcine mucosae, at the end of in vitro permeation study of tested
formulations [i.e., insulin (10 IU/ml) along with respective concentrations of HPβCD and
poloxamer 188] and control (PBS only), were immersed immediately into formalin
overnight at room temperature before being paraffin-embedded. Briefly, the tissues were
dehydrated using ethanol and water, followed by processing with xylene and finally
paraffin. Tissue sections cut into 5 µm sections and mounted on glass slides. Sections
were deparaffinized with xylene, rehydrated stepwise with ethanol and water, then
stained using hematoxylin and eosin stains. The images were taken using Zeiss Axiocam
506 color microscope (White Plains, NY) using 20X objective and 10X eyepiece.
4.4 Development of sublingual insulin film dosage form
Based on the developed sublingual insulin formulation, which included the
optimized concentrations of permeation enhancers, the sublingual insulin film dosage
form was developed.
4.4.1 Preparation of sublingual insulin film formulations
Firstly, aqueous solution of 40 % w/v polyvinyl alcohol (PVA) was prepared by
dispersing PVA in Nanopure® water using magnetic stirring. The solution was heated at
90° C until complete dissolution of PVA was achieved as reported (44). PVA (40% w/v)
was diluted with appropriate volume of 0.1 N HCl to achieve required polymer
concentration prior to which respective amounts of insulin and plasticizer (e.g., sorbitol)
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were dissolved in 0.1 N HCl. After vortexing and centrifuging, specific volume of the
solution was then cast on to aluminum film applicator (Elcometer, Warren, MI). The
dried film was then further characterized.
4.4.1.1 Preliminary screening
The PVA based sublingual insulin films were prepared and characterized to study
effect of PVA concentration, insulin concentration, and type of plasticizer on thickness,
drug loading, and disintegration time. The composition of sublingual insulin films is
summarized in Tables 6, 7, and 8, respectively.
4.4.1.1.1 Effect of PVA concentration
PVA is a widely used film-forming agent. Also, PVA concentration is important
in order to form a good film. For this, the solution should have enough viscosity not only
to form a good film but also should be viscous enough to be poured on to the film
applicator. Also, upon drying, it should get easily peeled off. Since the viscosity of PVA
increases with increase in concentration, hence PVA concentrations at 25, 30, and 35%,
(formulations A1-A3) respectively, were evaluated to formulate the film, keeping all
other factors constant.
4.4.1.1.2 Effect of insulin concentration
The effect of insulin concentration was studied with the aim of determining the
dose which could be loaded onto desired size of the film. The insulin concentrations
considered in this study were 0.25, 0.5, and 1 mg/ml, (formulations B1-B3), respectively,
keeping a constant PVA concentration based on the study.
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4.4.1.1.3 Effect of type of plasticizer
Plasticizers are needed for the films to achieve required flexibility, which makes
them easy to handle. Sorbitol, glycerin and PEG 400 (formulations C1-C3) have been
widely used as plasticizers, which were studied in this investigation at 5% concentration
level (i.e., 16.67% of PVA), keeping PVA, and insulin concentrations constant as studied
previously.
4.4.1.2 Effect of optimized concentrations of permeation enhancers
After the preliminary screening, the concentration of PVA, insulin, and the type
of plasticizer were evaluated in this study. In addition, the optimized concentrations of
permeation enhancers were included in preparation of this film (i.e., Formulation D).
Upon evaluation of this formulation, it could be checked whether inclusion of permeation
enhancers could influence any of the considered film characteristics.
4.4.1.3 Effect of insulin content
Based on the preliminary screening, increasing insulin content into the PVA film
was evaluated. The approach of increasing the thickness of the film was employed to
achieve desired insulin content in 2 by 2 cm size of the film. Based on the polymer
content, during the preliminary screening the dry and wet film thickness was determined
for previously formed 2 by 2 size films. Using the film applicator, the thickness was set
as wet film thickness while, the thickness measured upon drying was designated as dry
film thickness.

Dry film thickness = wet film thickness  solid content

Equation 2
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Based on the results of preliminary studies and equation 2, wet thickness was
calculated in order to achieve required drug loading on to 2 by 2 cm size film (i.e.,
Formulation E).
4.4.2 Evaluation of sublingual insulin film dosage form
PVA based sublingual insulin films were characterized for thickness, drug
loading, disintegration time, mechanical properties, in vitro dissolution, permeation, and
stability.
4.4.2.1 Thickness
The thickness of the different ﬁlms was measured using a digital micrometer
(Marathon, Ontario, Canada) with an accuracy of 0.001 mm in at least 4 different
locations of the ﬁlm and the average thickness was reported.
4.4.2.2 Drug loading
Drug loading was determined from films cut in 2 by 2 cm, which were then
dissolved in 5 ml of phosphate buffer solution (PBS, pH 6.8). The insulin content of the
samples was determined by the HPLC.

4.4.2.3 Disintegration time
Disintegration test was performed by placing a ﬁlm of size 2 by 2 cm in a glass
petri dish containing 5ml of PBS, pH 6.8. It was stirred at every 10-s time interval (39).
The time required for the ﬁlm to disintegrate was recorded.
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4.4.2.4 Mechanical characterization
The films were characterized by their mechanical properties using TA.XTPlus
Texture Analyzer (Texture Technologies Corp., Hamilton, MA). The stress-strain curves
were generated using TA settings of pre-test speed of 1mm/sec, test speed of 2 mm/sec,
and target mode of distance. For formulations D and E, 5 and 50 kg load cells were used,
respectively. Based on these curves, the breaking force, tensile strength, young’s
modulus, and percent elongation were generated.
4.4.2.5 In vitro dissolution studies
The in vitro dissolution studies were performed in PBS pH 6.8 and simulated
saliva. Briefly, the films were placed in 6 well plates containing 5 ml pH 6.8 or simulated
saliva, respectively, at 37 ± 0.5°C and under 50 rpm on shaking water bath, periodically
collecting 200 μl samples with replacement by fresh media (45).
4.4.2.6 In vitro permeation studies
Cellulose acetate membrane (with a pore size of 0.45 µm) was used as an artificial
membrane for permeation studies. The in vitro permeation studies were carried out using
side-by-side permeation cells (PermeGear, Hellerton, PA) with a permeation surface area
of 0.64 cm2 and a capacity of 3.5 ml for the donor and the receptor compartments. The
cellulose acetate membrane was sandwiched between the two compartments, and the
formulations were evaluated. Each formulation consisted of the sublingual insulin film of
2 by 2 of size with desired insulin content or sublingual insulin solution, which consisted
of insulin with the optimized concentrations of permeation enhancers. The formulation
was placed in the donor compartment, while phosphate buffer saline (PBS) was placed in
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receptor compartment. The temperature was maintained at 37 ± 0.5°C by circulating
water jackets (VWR International, Aurora, CO). Samples (200 µl each) were withdrawn
from the receptor compartment at 15, 30, 45, 60, 75, and 90 minutes and replaced by an
equal volume of fresh PBS. The insulin content of the withdrawn samples was
determined by the HPLC. Each formulation was tested in triplicate.
4.4.2.7 Stability of sublingual insulin film dosage form
The sublingual insulin films were stored at room temperature (25 ± 2°C) and in
the refrigerator (2-8°C). At each time point, i.e., 0, 3, 7, 14, 28, and 60 days, a 2 by 2 size
of the film was cut and analyzed for general appearance and drug loading.
4.5 Statistical analysis
Data for in vitro performance is represented as mean ± standard deviation (SD)
and in vivo performance as mean ± standard error of mean (SEM). To confirm
statistically significant difference between sublingual insulin formulations and respective
controls, t-test would be applied wherever applicable considering appropriate parameter
for comparison at an α value of 0.05.
5. Results and discussion
5.1 Development of sublingual insulin solution dosage form
The in vitro performance of permeation enhancers (i.e., HPβCD and poloxamer
188) was first evaluated at various concentrations across cellulose acetate membrane to
screen the suitable concentration of permeation enhancers. Upon identifying the suitable
concentration of permeation enhancers, permeation effects of HPβCD and poloxamer
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188, on insulin were evaluated using MatTek tissue model, MDCK cell line, rat and
porcine esophagus.
5.1.1 In vitro permeation studies
HPβCD and poloxamer 188 were evaluated at various concentrations across
cellulose acetate membrane to screen the suitable concentration. At first, as shown in
Figure 3, increasing the concentration of HPβCD from 0% to 5%, the cumulative amount
of insulin permeated increased, respectively. However, the cumulative amount of insulin
permeated at 10% level of HPβCD was observed less than that at 5% level. This could be
attributed to the fact that cyclodextrins suppress aggregation of insulin in a concentration
dependent manner (46). They may interact with hydrophobic amino acid residues of
insulin and thus prevent aggregation by eliminating intermolecular hydrophobic contacts.
It must be noted here that insulin in solution exists in an equilibrium between monomer,
dimer, hexamers (47). Thus, it could be observed that increase in concentration levels
from 0% to 2.5% and further to 5%, HPβCD could suppress the aggregation leading to
shifting to monomer form of insulin, and hence greater permeation through the pore size
of cellulose acetate membrane (Figure 3). On the other hand, HPβCD at 10%
concentration level may lead to steric hindrance leading to less permeation of insulin.
Taking this into consideration, 5% HPβCD was selected for further studies.
It was observed that increasing concentration of poloxamer 188 from 0% to
0.25%, the cumulative amount of insulin permeated increased (Figure 4). However,
further increasing concentration of poloxamer 188 from 0.25% to 0.5% and 1%, the
cumulative amount of insulin permeated was decreased, respectively. Since poloxamer
188 has been reported to have critical micelle concentration at 1% level, formation of
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micelles might lead to a decrease in insulin permeation through the pore size of cellulose
acetate membrane (48, 49). Also, it has been reported that the viscosities were found to
increase with increase in poloxamer 188 concentrations (50). Hence, the permeation may
decrease owing to increase in viscosity of donor medium. Further, 0.5% of poloxamer
188 has shown highest absorption when studied for its permeation enhancing effect (32).
Therefore, 0.5% poloxamer 188 was selected for further studies.
Further, based on the results as shown in Figures 3 and 4, 5% HPβCD and 0.5%
poloxamer 188 were considered and used as suitable concentrations of permeation
enhancers for further evaluations across MatTek tissue model, MDCK cell line, rat and,
porcine esophagus.
5.1.1.1 MatTek tissue model
MatTek’s EpiOral™ buccal tissue was considered based on the anatomical
similarities between buccal and sublingual mucosae, due to unavailability of a tissue
model for sublingual mucosa. Until now, in vitro studies for insulin using EpiOral™
tissue model have used either RP-HPLC or Bradford assay, respectively, for insulin
analysis (34, 51). In this study, insulin could not be detected due to lower sensitivity for
the samples analyzed using RP-HPLC. On the other hand, Bradford assay estimates total
protein content and is not specific to insulin. Hence, the samples were analyzed using
ELISA, which helps in not only quantitative analysis but also qualitative analysis, which
is specific for insulin. Further, during the first trial of the experiment, it was observed that
0 IU/ml (i.e., blank) indicated presence of insulin after analysis by ELISA (data not
shown). Upon contacting the manufacturer, it was found out that the assay medium
composition contained insulin, which was required for proper growth of cells. During
34

equilibration, the insulin from assay medium was taken up by tissues saturating the
tissues with insulin. Due to this reason, insulin content was not seen to increase with
increase in concentration of insulin from 5 to 10 IU/ml. However, in the succeeding two
trials, the assay medium was replaced by DPBS. After analyzing the samples of these two
trials, it was observed that in presence of permeation enhancers, insulin permeation was
higher, as seen in Figure 5 owing to the action of permeation enhancers as discussed
previously. Based on these results using EpiOral™ tissue model, it could be seen that the
combination of 5% HPβCD and 0.5% poloxamer 188 improved permeation of insulin.
Although this tissue model is more physiologically relevant, due to high cost, it was not
considered in further studies.
5.1.1.2 MDCK cell line
As seen in Figure 6, it was observed that the combination of 5% HPβCD and
0.5% poloxamer 188 showcased higher permeation of insulin across MDCK cell line as
compared to insulin without permeation enhancers which was found to be similar as seen
across EpiOral™ tissue model. Yet, it has to be noted that MDCK cells have been shown
to differentiate into columnar epithelium and to form tight junctions when cultured on
semipermeable membranes (37). On the other hand, sublingual mucosa is made up of
stratified squamous epithelium and does not exhibit tight junctions. Hence, although
higher permeation of insulin was observed across MDCK cell line, there was a need for
further investigation of an anatomically relevant tool.
5.1.1.3 Rat esophagus
The structural and anatomical similarities between esophagus and oral mucosa
have been reported (52). In this investigation, as seen in Figure 7, it could be observed
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that the combination of 5% HPβCD and 0.5% poloxamer 188 improved permeation of
insulin when evaluated across the rat esophagus.
Since this research involved use of SD rats, tissue excision was considered after
euthanization of the rats. Upon excision of the sublingual tissue, it was observed that due
to small surface area, it was difficult to cut required size of the tissue in order to mount it
on the side-by-side permeation cells. Also, the small size limits the number of tissues
available per animal to conduct the in vitro permeation studies. Longer length of
esophagus enables a greater number of tissues as compared to sublingual tissue.
On the contrary, rat esophagus as well as limits the number of tissues available to
conduct the permeation studies. Further, owing to dependency on animal euthanization
and limited number of rats, use of this tissue for permeation studies was found to be less
feasible. Hence, further attempts included to investigate more feasible alternatives to
evaluate in vitro performance.
5.1.1.4 Porcine esophagus
As compared to all above models used, porcine esophagus was easy to procure,
feasible to use, and provides larger, intact surface area. Also, the pig esophageal mucosa
has shown equivalence to buccal mucosa not only in histological terms, but also with
respect to its permeability. In the buccal mucosa, the permeability barrier is located in the
upper one-third of epithelium, and it is formed by lipids extruded from membranecoating granules (MCG) (53). MCG has been found in esophageal epithelium. Their
appearance and localization are similar to those in the buccal mucosa and has been
correlated to the performance of the permeability barrier (54).
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In addition to the other models, the permeation effects of HPβCD (5%),
poloxamer 188 (0.5%), and their combination, respectively, on insulin were further
evaluated across porcine esophagus. As shown in Figure 8, the cumulative amounts of
insulin permeated at 60 minutes in presence of HPβCD (5%), poloxamer 188 (0.5%), and
their combination were 3.86, 4.49 and 4.99 IU/cm2, respectively. This finding indicates
an additive effect on the cumulative amount of insulin permeated at 60 minutes in
presence of both HPβCD and poloxamer 188. Furthermore, the cumulative amount of
insulin permeated at 60 minutes was higher in presence of both HPβCD and poloxamer
188 than control group without the presence of permeation enhancers (Figure 9). These
results might be attributed to the mechanism of action of HPβCD and poloxamer 188 on
to the porcine esophagus. It has been reported that HPβCD acts as a permeation enhancer
by extracting the cholesterol from the membrane, which may cause the increase of
fluidity and loosening of the lipid bilayer (23, 55).
On the other hand, it has been reported that poloxamer 188 is a more effective
permeation enhancer than HPβCD, which is in accordance with the results in this study
(Figure 9) (23, 31). In addition, poloxamer 188 has been reported to insert into the lipid
bilayer and hence loosening of the lipid bilayer due to its highly surface-active nature
which may aid in absorption by facilitating its insertion into lipid monolayers (48).
Further, porcine esophagus could be used to evaluate various sublingual insulin
formulations, as seen in Figure 10. It could be observed that in presence of the
combination of permeation enhancers, with increase in insulin concentration from 5 to 10
IU/ml, the permeation of insulin increased, but increase in insulin concentration from 10
to 15 IU/ml, the permeation of insulin decreased, respectively. Hence, the in vitro
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permeation studies across porcine esophagus indicate that the combination of permeation
enhancers [i.e., HPβCD (5%) and poloxamer 188 (0.5%)] could be further evaluated for
in vivo performance. Also, permeation studies across porcine esophagus have
demonstrated that it could be proposed as a tool for in vitro performance evaluation.
5.1.2 In vivo studies
The sublingual insulin formulations consisting of HPβCD (5%) and poloxamer
188 (0.5%) were evaluated for the in vivo performance in SD rats in terms of various
doses of insulin and effect of the permeation enhancers.
5.1.2.1 Evaluation of dosages for sublingual insulin formulations
Although various routes of insulin delivery have been examined, no single study
has examined effective doses of sublingual insulin formulations in SD rats. Hence, in the
current study, three different doses of insulin in the presence of the permeation enhancers
were examined. Briefly, the sublingual insulin formulations at dose of 5, 10, 15 IU/kg,
respectively, along with 5% HPβCD and 0.5% of poloxamer 188 were administered
sublingually to SD rats. For the comparison, sublingual saline and subcutaneous insulin
solutions (1 IU/kg), respectively, served as controls.
The mean blood glucose profiles after administration of sublingual insulin
formulations at 5, 10, and 15 IU/kg, respectively, along with 5% HPβCD and 0.5%
poloxamer 188, are shown in Figure 11. The basal blood glucose levels start reducing
after insulin administration at 5 IU/kg and reach the nadir at 90 minutes, and thereafter
the blood glucose levels start to increase and return to the baseline level. Similar results
were observed for the other two doses (i.e., 10 and 15 IU/kg). Thus, these profiles depict
that the sublingual insulin formulations play a role in reducing the blood glucose levels in
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SD rats. On the other hand, after administration of saline (i.e., negative control), only
slight reduction in the blood glucose levels was observed.
In addition to the blood glucose profiles, serum insulin concentrations were
analyzed after sublingual insulin administration at 5, 10, and 15 IU/kg, respectively,
along with 5% HPβCD and 0.5% poloxamer 188 and are shown in Figure 12. It was
observed that at the dose of 15 IU/kg, serum insulin concentration increased with time
and, after reaching a maximum concentration, declined at the end of 210 minutes. At the
dose of 5 and 10 IU/kg, similar observations were observed. Moreover, the profiles
followed a trend indicating with an increase in dose, the serum insulin concentrations
increased. In terms of subcutaneous insulin administration, insulin was detected at 10
minutes, followed by a rapid decrease to the end of experiments.
Based on profiles shown in Figures 11 and 12, several pharmacodynamic and
pharmacokinetic parameters were calculated and compared. The parameters were
calculated for each animal and then represented as mean, as shown in Table 1. The basal
blood glucose levels demonstrate the variation between the basal values within the
various groups of rats. Cnadir and Tnadir represent the minimum blood glucose levels and
the time required to achieve these levels, respectively. These pharmacodynamic
parameters were further used for the comparison among various rat groups. The mean
basal blood glucose levels (range from 139.9 to 185.1 mg/dl) indicate the variation
among the various groups of rats used in this investigation. Since the basal blood glucose
levels in each group were different, the percentage of maximum decrease in glucose level
was calculated. As displayed in Table 1, it was observed that with an increase in dose of
insulin from 5, 10, to 15 IU/kg, percentage of maximum decrease in glucose level also
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increased from 23.41%, 31.52% to 36.48%. However, with an increase in dose from 5 to
10 IU/kg of insulin, the percentage of maximum decrease in glucose level increased by
8.11%, while the increase in dose from 10 to 15 IU/kg was 4.96% only. In addition, it
was observed that with increase in dose from 5 to 10 IU/kg of insulin, the mean value of
Tnadir increased from 1.38 to 1.92 hours but decreased to 1.75 hours at 15 IU/kg of
insulin.
On the other hand, pharmacokinetic parameters of serum insulin concentrationtime curves, such as peak insulin concentration (Cmax), the time to reach the serum peak
level (Tmax), and mean residence time MRTlast, were determined and displayed in Table 1.
The mean value of Cmax increased from 2.51, 5.88, and 38.24 µIU/ml with increase in
dose of insulin from 5, 10, and 15 IU/kg, respectively. Moreover, the mean value of Cmax
was observed to be higher for insulin at 15 IU/kg than that at 5 and 10 IU/kg. A similar
result has been reported in another study wherein buccal insulin was administered to SD
rats at three doses. In this study, it was observed that the highest dose of insulin produced
a slightly higher than expected insulin level than that of the other two doses (56). In
addition, increase in Cmax denotes increase in the reduction in glucose level. Moreover,
the mean value of MRTlast for insulin was lower (0.56 hours) in absence of permeation
enhancers as compared to in presence of permeation enhancers (1.46 hours), which
correspondingly relates to its pharmacodynamic responses (i.e., later shows more
reduction in glucose levels).
5.1.2.2 Effect of permeation enhancers
In addition, the permeation enhancers [i.e., HPβCD (5%) and poloxamer 188
(0.5%)] were evaluated for their effectiveness in vivo using SD rats. Briefly, the
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sublingual insulin formulations at dose of 15 IU/kg along with 5% HPβCD and 0.5% of
poloxamer 188 were administered sublingually to SD rats. For the comparison,
sublingual saline, subcutaneous insulin (1 IU/kg), sublingual insulin (15 IU/kg) without
permeation enhancers, and only permeation enhancers, respectively, served as controls.
Figure 13 demonstrates the effectiveness of permeation enhancers (i.e., 5%
HPβCD and 0.5% poloxamer 188). It was observed that insulin in presence of 5%
HPβCD and 0.5% poloxamer 188 had shown reduction in the blood glucose levels as
compared to insulin in absence of permeation enhancers. It must be noted that the use of
HPβCD at 5% concentration level and poloxamer 188 at 0.5%, respectively, is in
accordance with the literature. HPβCD at 5% has shown to be effective as permeation
enhancer in SD rats (23). Also, it has been reported that at concentration of HPβCD
greater than 5% level led to less absorption when studied as a permeation enhancer in
vivo (27, 31). On the other hand, it has been reported that for poloxamer 188, the
absorption decreases at concentration greater than 1% (9). It has also been reported that
poloxamer 188, when evaluated at concentration levels lower than 0.5%, led to less
absorption (31, 32). This supports the use of poloxamer 188 at 0.5% concentration level.
Hence, the selection of concentration of permeation enhancers was not only in
accordance with the literature but also in sync with the results of this study. Based on the
results discussed above and Figure 11, insulin at dose of 10 and 15 IU/kg, respectively,
along with 5% HPβCD and 0.5% of poloxamer 188, could be evaluated further based on
the higher hypoglycemic effect observed as compared to 5 IU/kg. On the contrary, in
Figure 14, it was clearly seen that serum insulin concentrations in presence of 5%
HPβCD and 0.5% poloxamer 188 were higher than that in absence of permeation
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enhancers. It must be noted here that although the collected blood samples were analyzed
for saline and permeation enhancers only, no insulin could be detected.
Based on Figures 13 and 14 and Table 1, the percentage of maximum decrease in
glucose level did not show any significant difference in presence of only the permeation
enhancers (p > 0.05 as compared to saline using t-test). This finding indicates that the
incorporated permeation enhancers do not contribute to the hypoglycemic effect.
Furthermore, percentage of maximum decrease in glucose level was found to be
significantly different (p < 0.05) for insulin in absence of the permeation enhancers as
compared to that of in presence of the permeation enhancers (Table 1). This result
supports the claim that the use of these permeation enhancers (i.e., 5% HPβCD and 0.5%
poloxamer 188) is effective in improving hypoglycemic performance of insulin.
Based on the results discussed above, it was observed that the increase in dose
from 10 to 15 IU/kg led to reduction in blood glucose levels by 4.96% only. Also, at the
dose of 15IU/kg, the blood glucose levels could not reach baseline owing to higher serum
insulin levels of 38.24 µIU/ml. On the other hand, insulin at dose of 10 IU/kg has shown
31.52% reduction in blood glucose levels with serum insulin levels of only 5.88 µIU/ml.
Hence, it could be concluded that insulin at dose of 10 IU/kg along with HPβCD (5%)
and poloxamer 188 (0.5%) is suitable for development of insulin solution for sublingual
administration.
5.1.3 Application of design of experiments
Based on the in vitro permeation studies across porcine esophagus, synergistic
effect of HPβCD and poloxamer 188 was observed in order to improve permeation of
insulin. In addition, as per in vivo studies as well, insulin at dose of 10 IU/kg along with
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HPβCD (5%) and poloxamer 188 (0.5%) could be considered suitable for development of
insulin solution for sublingual administration. Hence, considering the design space
around this formulation, in the current investigation, a three-level resolution III fractional
factorial design was employed to optimize the insulin permeation statistically.
5.1.3.1 Optimization of concentration of insulin and permeation enhancers across porcine
esophagus
Using the three-level resolution III fractional factorial design, formulations were
prepared and placed on side-by-side permeation cells, as described previously. Based on
the in vitro permeation studies across porcine esophagus, cumulative amount permeated
at 60 minutes was determined, as shown in Table 2. The data were analyzed to study the
effect of the independent variables on the response by applying multiple regression
analysis on the experimental data. Equation 3 was derived based on coded variables and
represented the normalized coefficients showing the relative impact of the variables on Y.
𝑌 = + 4.0800 + 0.3050 (𝑋1 ) + 0.2667(𝑋2 ) − 7800 (𝑋3 ) − 1.2750(𝑋1 )2 −
0.5867(𝑋2 )2 − 0.7900 (𝑋3 )2 − 0.3433(𝑋1 ∗ 𝑋2 ) + 0.5200 (𝑋1 ∗ 𝑋3 ) +
0.1033 (𝑋2 ∗ 𝑋3 )

Equation 3

This quadratic model suggested that the sufficiency of quadratic model be used
for further analysis based on R2 value (0.7019) and standard deviation (2.1637). A
positive sign indicates synergistic effect, and a negative sign signifies an antagonistic
effect. For instance, response Y will increase with increase in X2 since it has a positive
sign. Also, the value of the normalized coefficient suggests the relative impact on Y for
each factor. For example, since X3 has the highest value, this indicates that among all the
independent variables, X3 has the highest impact on Y. It could be noted that X3 is an
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established permeation enhancer with a very narrow range of effective concentrations to
exert permeation effects. This narrow range of concentration may lead to a negative sign.
Further, X2 and X3 interaction term has the highest value confirming the previously
observed synergistic effect.
Although equation 3 represents the normalized coefficients and helps to
understand relative impact of independent variables, to predict the cumulative amount
permeated at 60 minutes, equation 4 should be considered which is based on actual
variables. This equation was used to predict cumulative amount permeated at 60 minutes
for each experimental run and for the construction of contour and interaction plots.
𝑌 = − 2.943333 + 1.253667 (𝑋1 ) − 0.064667(𝑋2 ) − 3.473333(𝑋3 ) −
0.51000(𝑋1 )2 + 0.023467 (𝑋2 )2 − 3.160000 (𝑋3 )2 − 0.013733(𝑋1 ∗ 𝑋2 ) −
0.208000 (𝑋1 ∗ 𝑋3 ) + 0.041333 (𝑋2 ∗ 𝑋3 )

Equation 4

Figure 15 depicts two-dimensional contour plots which are useful in studying the
effects of two independent variables on the response at one time. As shown in the legend,
each color depicts a level for Y. It could be observed that among all the three levels of
insulin (X1) (Figures 15A-C), highest cumulative amount permeated at 60 minutes i.e.,
response (Y) was observed to be at 10 IU/ml of insulin in presence of HPβCD (X2) and
poloxamer 188 (X3). Also, interestingly, response (Y) increased with increase in X2 and
decrease in X3. Further, Figures 14 and 15 show interaction plots which are known to
study the interaction effects of the independent variables on the response. Figure 16
shows the interaction effect of concentration of X2 and X3 on Y at 10 and IU/ml of X1.
The two lines in the plot represent upper and lower levels of X3. Since the two lines do
not intersect each other, it could be concluded that there is no interaction between the
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independent variables X2 and X3. Similar observation was seen at 5 and 15 IU/ml of
insulin. Also, Figure 17 shows the interaction effect of concentration of X1 and X2 on Y
at 0.5 % of poloxamer 188 (X3). However, it could be observed that the two lines in this
interaction plot intersect as the concentration of insulin increases above 10 IU/ml.
As seen in Table 2, the cumulative amount permeated at 60 minutes for
formulation F9 was highest (5.612 ± 0.286 IU/cm2). Since this finding is in accordance
with previous studies, it could be concluded that the response increases in presence of
permeation enhancers (i.e., HPβCD and poloxamer 188). Moreover, it was also observed
that this observation was consistent at all the three levels of insulin (Figure 10). On the
other hand, it was observed that at 15 IU/ml (X1), with increase in concentration of X3
from 0.5 (formulation F4) to 1% (formulation F3), response Y decreases. Also,
formulation F3 has shown the lowest cumulative amount permeated at 60 minutes (1.583
± 1.803 IU/cm2). This could be attributed to the reported critical micelle concentration of
1% (for poloxamer 188), which might lead to the decrease in insulin permeation across
the porcine esophagus (48). Further, increase in concentration from 10 to 15 IU/ml for X1
and from 5 to 10 % for X2 i.e., formulation F4 and F9, respectively have shown decrease
in Y (at same level of X3). Also, it could be noted that for formulations F1, F3, and F4
(i.e., at 15 IU/ml for X1), response Y is less compared to 10 IU/ml of X1. This could be
because of formation of insulin aggregates, which are reported to be formed at high
concentration that could lead to decrease in Y across the porcine esophagus (57).
As discussed above, although X2 and X3 do not interact at all the levels of X1,
interestingly, at higher levels of X3 and X1, some interaction was observed. It could be
clearly noted that the response Y increased with high level of X2 and low level of X3.
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Based on this data, it could be expected that the optimized formulation should have
higher level of X2 and lower level of X3. Such a scenario depicts a good example where
optimization could be performed using a design which helps to study the effect of two
independent variables simultaneously on the response using minimum number of runs.
As per FusionPro software, the three settings available for optimization are:
maximize, minimize, or target range. In this study, the optimization of the formulation
(X1:X2:X3) was carried out by keeping setting as maximize. Among the three checkpoint
formulations in Table 3, first formulation (10:10:0.3) is as per maximum optimized
settings, which predicts Y of 5.09 IU/cm2. Also, point prediction of the FusionPro
software was used to determine other two checkpoint formulations in order to get values
of 90 and 75% of Y (i.e., 5.09 IU/cm2). Based on the percent prediction error displayed in
Table 3, it could be observed that this model could be employed to predict a response
within 15-20% of variation. Hence, it could be concluded that sublingual insulin solution
was not only optimized but also validated using design of experiments approach.
In addition, it has been reported that cumulative amount of 2.56 IU/cm2 of insulin
has shown therapeutic effect after buccal administration (38, 56). Since the aim of buccal
administration is to deliver basal insulin, lower amount of insulin is required to maintain
normal blood glucose level. Hence, it could be expected that for sublingual
administration wherein the aim is to deliver bolus insulin, higher amount of insulin will
be required. Based on this, the optimized Y of 5.09 IU/cm2 should be sufficient to elicit a
therapeutic response for sublingual insulin solution.
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5.1.3.2 In vivo evaluation of optimized sublingual insulin formulations
Based on the design of experiments as discussed in previous section, it was found
out that the optimized concentrations of X1:X2:X3 were (10:10:0.3), respectively. This
formulation was further evaluated in vivo for its hypoglycemic activity. As seen in Figure
18, the mean blood glucose profiles after administration of sublingual insulin formulation
at 10 IU/kg, along with 10% HPβCD and 0.3% poloxamer 188 depicted that the basal
blood glucose levels start reducing after insulin administration and reach the nadir at 90
minutes, and thereafter the blood glucose levels start to increase and return to the baseline
level. In addition, it could be noted that the blood glucose profile was similar to
sublingual insulin formulation at 10 IU/kg, along with 5% HPβCD and 0.5% poloxamer
188. Similarly, mean serum insulin profiles could be compared, as seen in Figure 19. It
was observed that at the dose of 10 IU/kg, serum insulin concentrations for optimized
formulation reached a maximum concentration, and then declined at the end of 210
minutes which was like sublingual insulin formulation at 10 IU/kg, along with 5%
HPβCD and 0.5% poloxamer 188. Further, as shown in Figure 20, the optimized
formulation administered at three different doses, i.e., 2.5, 5, and 10 IU/kg could depict
reduction in blood glucose levels. Furthermore, with increase in dose of insulin, the
reduction in blood glucose levels increased. On the other hand, although blood samples
were collected for insulin at the dose of 2.5 and 5 IU/kg, no insulin could be detected.
Based on Figures 18, 19, and 20, the pharmacodynamic and pharmacokinetic
parameters were calculated and compared, as represented in Table 5. As discussed
previously, the following pharmacodynamic parameters: basal blood glucose levels,
Cnadir, Tnadir, and percentage of maximum decrease in glucose level were considered for
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the comparison among various rat groups. The mean basal blood glucose levels (range
from 113.0 to 109.3 mg/dl) indicate the variation among the various groups of rats used
in this investigation. Since the basal blood glucose levels in each group were different,
the percentage of maximum decrease in glucose level was calculated. As displayed in
Table 5, it was observed that with an increase in dose of insulin from 2.5, 5, to 10 IU/kg,
percentage of maximum decrease in glucose level also increased from 9.4%, 24.8% to
26.7%. In addition, although Cnadir was observed to decrease, the mean value of Tnadir was
found to be almost similar to increase in dose of insulin. Moreover, percentage of
maximum decrease in glucose level of the optimized formulation was found to be similar
(i.e., 26.7%) to that of insulin at 10 IU/kg along with HPβCD (5%) and poloxamer 188
(0.5%)(i.e., 31.5%).
On the other hand, pharmacokinetic parameters of serum insulin concentrationtime curves, such as peak insulin concentration (Cmax), the time to reach the serum peak
level (Tmax), and mean residence time MRTlast, were determined and displayed in Table 5.
The mean value of Cmax was found to be 3.6 and 5.88 µIU/ml, respectively, for the
optimized formulation and insulin at 10 IU/kg along with HPβCD (5%) and poloxamer
188 (0.5%). In addition, decrease in Tmax from 90 to 60 minutes could indicate that in
presence of optimized concentrations fastened the action of HPβCD and poloxamer 188.
Reduction in Tmax has been reported for fluoxetine in presence of combination of
permeation enhancers as compared to control (58). Moreover, the mean value of MRTlast
for insulin was also found to be similar for both the formulations. Hence, although the
optimized formulation displayed similar reduction in blood glucose levels, it indicates
faster action which, could be beneficial in formulating sublingual insulin formulations.
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5.1.3.3 Safety of permeation enhancers
Microscopic evaluation of mucosal tissue cross-sections has been widely used as
an easy and practical method for assessing any damaging effect associated with exposure
to enhancer (24, 59). It must be noted that the porcine esophageal mucosa and sublingual
mucosa are anatomically similar (i.e., the presence of squamous epithelium). Hence,
following in vitro permeation study for formulation containing insulin (10 IU/ml) along
with HPβCD (5%) and poloxamer 188 (0.5%), (10 IU/ml) along with HPβCD (10%) and
poloxamer 188 (0.3%), and control, PBS showed that membrane integrity appeared to
remain undamaged (Figure 21), suggesting HPβCD (5%) and poloxamer 188 (0.5%) as
safe permeation enhancers. Nevertheless, changes following chronic administration of
both enhancers need to be evaluated. In addition, after treatment sections revealed
epithelial detachment and mild acantholytic alterations (gaps) (Figure 21 B-C) which,
could be attributed to an increase in intercellular space and swelling related to increased
permeation (60).
5.2 Development of sublingual insulin film dosage form
As discussed previously, insulin at the dose of 10 IU/mL was considered suitable
based on the in vivo evaluation. Also, as per design of experiments, sublingual insulin
formulation included the optimized concentrations of permeation enhancers [i.e., HPβCD
(10%) and poloxamer 188 (0.3%)] were considered further to develop the sublingual
insulin film dosage form.
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5.2.1 Preliminary screening
The PVA based sublingual insulin films were prepared and characterized to study
effect of PVA concentration, insulin concentration, and type of plasticizer on thickness,
drug loading, and disintegration time.
5.2.1.1 Effect of PVA concentration
PVA has been employed in drug delivery due to its good film-forming property,
mechanical property, and biocompatibility (61). Based on the literature, formulation
using 20 % PVA was prepared, but due to less viscosity (based on visual observation), it
was not considered in further studies (62). Since with increase in concentration of
polymer concentration viscosity increases, 25, 30, and 35% PVA concentrations were
evaluated (i.e., formulations A1, A2, and A3, respectively). Further, it was observed that
for formulation A1, the film could not be peeled off easily, indicating that concentration
of the polymer was not enough to form the film. On the other hand, for formulations A2
and A3, the films could be not only formed but also peeled off easily. Also, as seen in
Table 6, it was observed that there was no difference observed in between formulations
A2 and A3 in terms of thickness, drug loading, and disintegration time. Hence, based on
lower polymer content formulation A2 (i.e., 30% PVA) was selected for further studies.
5.2.1.2 Effect of insulin concentration
Although with increase in concentration of insulin, there was no effect on
thickness, drug loading, and disintegration time, slight precipitation was observed at 1
mg/ml (Table 7). Since pH of PVA is around 5, and so is the isoelectric pH of insulin, at
higher concentration of insulin, precipitation could be observed. Hence, formulation B2
with lower insulin concentration of 0.5 mg/ml was selected for further studies.
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5.2.1.3 Effect of type of plasticizer
Further, based on the above studies, 30% PVA, and 0.5 mg/ml of insulin
concentration was used further to study the effect of plasticizers. Glycerin, PEG 400 and
sorbitol were evaluated as plasticizers represented as formulations C1, C2, and C3,
respectively. As displayed in Table 8, although there was no difference in terms of
thickness, formulation C1 demonstrated lower drug loading (86.5 ± 9.4 %) as compared
to formulation C2 and C3 (98.6 ± 10.0, 106.7 ± 8.0 %), respectively. This could be
attributed to the interaction between glycerin and 0.1 N HCl. On the other hand,
formulation C3 demonstrates lower disintegration time as compared to formulations C1
and C2. This could be because of better miscibility of sorbitol with PVA since both are
Parteck® products prepared by their advanced technology. Due to smaller particle size
(i.e., greater surface area), faster disintegration could be achieved. In addition, sorbitol
has been reported to be more effective than glycerol as a plasticizer in that films of equal
tensile strength, elongation, and elastic modulus with lower oxygen permeabilities when
plasticized using sorbitol (63). In addition, sorbitol provides sweet taste as well, and
hence, formulation C3 was selected for further studies.
5.2.2 Effect of optimized concentrations of permeation enhancers
Further, formulation C3 was incorporated with optimized concentrations of
permeation enhancers (i.e., formulation D). As shown in Table 9, slight increase in
thickness and disintegration time was observed for the formulation D, which could be
attributed to increase in solid content as compared to formulation C3. Nevertheless,
incorporation of permeation enhancers did not affect drug loading.
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5.2.3 Effect of insulin content
Based on the previous studies, it was observed that the dose of insulin that could
be incorporated in the film dosage form could be 10 IU. Hence, 10 IU was loaded in ﬁlm
of size 2 by 2 cm by increasing the thickness of the film to 250 µm (based on calculation
explained in methodology) (i.e., formulation E). Although the insulin content was
observed to be 106 ± 8%, the disintegration time achieved was of 170 ± 24 seconds
(Table 9).
5.2.4 Evaluation of sublingual insulin film dosage form
As discussed above, the sublingual insulin films were evaluated in terms of
thickness, drug loading, and disintegration time as a part of preliminary studies. Further,
the formulations D and E were evaluated for mechanical properties and in vitro
dissolution and permeation.
5.2.4.1 Mechanical characterization
Further, the films (formulations D, E, and Listerine®) were characterized for
strength and flexibility. The breaking force and tensile strength indicate the strength of
the film. On the other hand, the flexibility of the films was measured with respect to the
young’s modulus and percent elongation. These parameters were obtained using stressstrain curves (Figure 22) generated using Texture Analyzer. In this case, formulation D
and E were compared with Listerine® for strength and flexibility. As shown in Table 10,
breaking force and tensile strength are comparative, indicating enough strength for the
films. Also, it was observed that formulation D and E had shown lower values of
Young’s modulus, which indicate higher flexibility than Listerine®. Also, lower values
of Young’s modulus of ﬁlm indicate that it is not too rigid and hence could avoid
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unpleasant sensation in the sublingual cavity provided by rigid films as reported (64). In
addition, percent elongation is higher for formulation D and E as compared to Listerine®.
Hence, the formulated films have demonstrated satisfactory mechanical properties for
handling and packaging purposes.
5.2.4.2 In vitro dissolution studies
Figure 23 shows in vitro dissolution of formulation E in PBS, pH 6.8, and
simulated saliva. It was observed that within 30 minutes, 100% release was seen in PBS,
pH 6.8. Interestingly, it has been reported that the average interval in between swallows
was 30 minutes (i.e., individuals retain saliva for 30 minutes) (65). Hence, under the
assumption that there is no other factor contributing to change in this period, it can be
estimated that the entire dose of insulin is available at the absorption site.
5.2.4.3 In vitro permeation studies
In addition to in vitro dissolution, in vitro permeation was also conducted as
shown in Figure 24. Moreover, the cumulative amount permeated at 30 minutes was
found to be 1.13 ± 0.14 IU/cm2 and 1.00 ± 0.01 IU/cm2 for insulin solution, and
formulated film on dissolution, respectively, which were demonstrated to be similar.
Also, it could be observed that in vitro permeation flux of insulin in film (0.052 ± 0.011
IU/cm2/min) was found to be 64 % of the flux for insulin solution (0.081 ± 0.017
IU/cm2/min) formulation which could be attributed to contribution of viscosity of PVA
leading to less permeation. Hence, it can be concluded that the film on dissolution could
behave similarly to insulin solution and hence is a feasible approach for sublingual
administration.
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5.2.4.4 Stability of sublingual insulin film dosage form
Insulin is known to undergo various chemical (e.g., deamidation and covalent
dimerization), and physical (e.g., fibrillation, adsorption, aggregation and precipitation)
degradative processes (66, 67). However, it is expected that insulin in film dosage form
could be more stable than in solution dosage form. In this study, insulin content was
determined after subjecting the sublingual insulin films at two different temperatures [i.e.,
controlled room temperature (25 ± 2°C) and refrigeration (2-8°C)]. After evaluating at
predetermined time intervals, it was observed that the insulin content at both the
conditions was above 86% for 28 days (Figure 25).
During storage and use, insulin deteriorates via two main chemical reactions:
deamidation from hydrolysis and polymerization from the formation of intermolecular
covalent bonds with other insulin molecules to form higher molecular weight
transformation products. Deamidation is a reaction in which the side chain group in
glutaminyl or asparaginyl residues is hydrolyzed to form a free carboxylic acid. The six
residues in insulin which pose as potential deamidation sites are GlnA5, GlnA15,
AsnA18, AsnA21, AsnB3, and GlnB4. The asparagine (Asn) residues are more prone to
deamidation than glutamine (Gln) residues. Deamidation products essentially retain
native activity and are not associated with adverse immunogenicity (68). As shown in
Figure 25, the decrease in the insulin content could be attributed to these factors. In
addition, it was observed that the films stored at room temperature became softer,
indicating uptake of moisture. In addition, it has been reported that the aggregation of
insulin could increase with increase in moisture (69). This could explain lower insulin
content as compared to films stored in refrigerator (Figure 25).
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6. Conclusions
Treatment of Diabetes Mellitus and prevention of its long term complications
such as renal failure, cardiovascular diseases, and amputation have become increasingly
pressing clinical challenges all over the world. In order to administer bolus insulin where
there is a need for faster onset time, sublingual administration in the form of fast
disintegrating film for meal-time insulin seems an attractive option. Since evaluation of
film in vivo is not feasible due to smaller oral cavity of rats, sublingual insulin solution
dosage form was developed and then evaluated in vivo based on which the sublingual
insulin film dosage form was further developed.
In order to develop insulin solution dosage form, firstly, four models were
assessed for their suitability as a potential tool for in vitro sublingual permeation studies.
Based on the results of the permeation studies, feasibility, physiological relevance,
anatomical similarity, and cost-effectiveness, in the current research, porcine esophagus
has been selected as an alternative sublingual mucosa to study in vitro performance of
insulin. The cumulative amounts of insulin permeated at 60 minutes in presence of
HPβCD (5%), poloxamer 188 (0.5%), and their combination were 1.31, 3.23, and 4.99
IU/cm2, respectively. This finding indicates an additive effect on the cumulative amount
of insulin permeated at 60 minutes in presence of both HPβCD and poloxamer 188.
Hence, the in vitro permeation studies across porcine esophagus indicate that the
combination of permeation enhancers [i.e., HPβCD (5%) and poloxamer 188 (0.5%)]
could be further evaluated for in vivo performance.
After evaluating sublingual insulin at various dosages in vivo, insulin at dose of
10 IU/kg has shown 31.52% reduction in blood glucose levels with serum insulin levels
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of only 5.88 µIU/ml. This indicated that insulin at dose of 10 IU/kg along with HPβCD
(5%) and poloxamer 188 (0.5%) is suitable for development of insulin solution for
sublingual administration. Further, as per design of experiments, sublingual insulin
formulation included the optimized concentrations of permeation enhancers as HPβCD
(10%) and poloxamer 188 (0.3%). The optimized sublingual insulin formulation was
evaluated at various dosages in vivo. It was observed that with an increase in dose of
insulin from 2.5, 5, to 10 IU/kg, percentage of maximum decrease in glucose level also
increased from 9.4%, 24.8% to 26.7%. In addition, the membrane integrity appeared to
remain undamaged (Figure 21), suggesting safety of HPβCD and poloxamer 188
permeation enhancers.
Based on these studies, the optimized concentrations of permeation enhancers
[i.e., HPβCD (10%) and poloxamer 188 (0.3%)] were considered further to develop the
sublingual insulin film dosage form. After preliminary screening, the sublingual insulin
films were formulated and evaluated for thickness, insulin content, disintegration time,
mechanical properties, in vitro dissolution, and in vitro permeation studies, and stability.
Based on in vitro permeation studies, it can be concluded that the film on dissolution
could behave similarly to insulin solution and hence is a feasible approach for sublingual
administration.
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Tables
Table 1: Comparison of pharmacodynamic and pharmacokinetic parameters following
sublingual insulin administration along with controls to Sprague-Dawley rats (data
represent mean ± SEM, n = 3-6)

Parameter

Sublingual (Sl) insulin
with 5% HPβCD and 0.5%
of poloxamer 188
5
10
15
IU/kg IU/kg
IU/kg

Controls

Saline
(Sl)

Basal
blood
glucose
level
(mg/dl)
Cnadir
(mg/dl)

139.9
± 8.1

168.7
± 9.9

185.1
± 13.6

164.0
±
29.9

106.1
± 5.2

111.7
± 8.6

116.4
± 6.7

Tnadir
(h)

1.38
± 0.20

1.92
± 0.25

1.75
± 0.31

Maximum
decrease in
glucose
level (%)
Cmax
(µIU/ml)
Tmax (min)

23.41
*
± 1.35

31.52*
± 4.15

155.0
±
32.0
1.33
±
0.17
9.50
± 3.33

#$

36.48*
± 3.23

Subcut
aneous
(1IU/k
g)
136.7
± 5.1

15
5% HPβCD
&
IU/kg
and 0.5% of
(Sl)
poloxamer
188 (Sl)
137.7
126.3
± 6.1
± 10.7

67.7
± 6.9

107.1
± 4.9

102.3
± 4.5

1.75
± 0.25

1.83
± 0.44

1.50
± 0.25

50.10
± 5.56

23.34*
± 1.22

18.40
± 3.73

2.51
5.88
38.24
30.42
6.28
± 1.51 ± 1.75 ± 22.97
± 6.76 ± 3.26
55
90
108
10
37.5
± 35
±0
± 18
±0
±7
MRTlast (h) 1.74
1.33
1.46
0.16
0.56
± 0.13 ± 0.18
± 0.35
± 0.0
± 0.09
&
Insulin without 5% HPβCD and 0.5% poloxamer 188
*p < 0.05 as compared to saline using t- test; #p < 0.05 as compared to 0 IU/kg using ttest
$
p < 0.05 as compared to 15 IU/kg with 5% HPβCD and 0.5% poloxamer 188 using t-test
Cnadir, minimum glucose concentration; Tnadir, time to Cnadir; Cmax, maximum insulin
concentration; Tmax, time to Cmax; MRTlast, mean residence time
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Table 2: Three-level resolution III fractional factorial design containing independent
variable along with levels and dependent variable
Level
Independent variable
X1: Concentration of

Low (-1)

Medium (0)

High (+1)

5

10

15

0

5

10

0

0.5

1

insulin (IU/mL)
X2: Concentration of
HPβCD (% w/v)
X3: Concentration of
poloxamer 188 (% w/v)
Dependent variable (Y): Cumulative amount permeated at 60 minutes (IU/cm2)
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Table 3: Composition of formulations as per three-level resolution III fractional factorial
design and cumulative amount permeated at 60 minutes obtained after conducting the in
vitro permeation studies for the runs (data represent mean ± SD, n=3)

Formulation

Y

code

X1

X2

X3

F1

15

5

0.0

3.616 ± 1.236

F2

5

5

0.5

2.553 ± 0.443

F3

15

0

1.0

1.583 ± 1.803

F4

15

10

0.5

3.618 ± 1.391

F5

10

5

1.0

2.505 ± 0.278

F6

5

10

1.0

2.754 ± 0.633

F7

5

0

0.0

2.049 ± 0.373

F8

10

0

0.5

4.402 ± 0.645

F9

10

5

0.5

5.612 ± 0.286

F10

10

10

0.0

4.823 ± 0.433

X1: Concentration of insulin (IU/mL); X2: Concentration of
HPβCD (% w/v); X3: Concentration of poloxamer 188 (% w/v);
Y: Cumulative amount permeated at 60 minutes (IU/cm2)
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Table 4: Composition of checkpoint formulations with observed and predicted values of
cumulative amount permeated at 60 minutes (experimental data represent mean ± SD,
n=3)

Check point
formulation
composition

Y
Observed value

Predicted value

% prediction error

6.47

5.09

21.28

(X1:X2:X3)
(10:10:0.3)

± 0.14
(10:8:0.3)

5.20

± 1.79
4.53

± 0.40
(15:10:0.3)

3.56
± 0.45

12.43
± 6.82

3.97

14.41
± 3.23
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Table 5: Comparison of pharmacodynamic and pharmacokinetic parameters following
sublingual insulin administration of sublingual insulin formulations along with controls to
Sprague-Dawley rats (data represent mean ± SEM, n = 3-6)

Parameter

Basal
blood
glucose
level
(mg/dl)
Cnadir
(mg/dl)
Tnadir
(h)
Maximum
decrease
in glucose
level (%)
Cmax
(µIU/ml)
Tmax (min)

Sublingual (Sl) insulin with
10% H and 0.3% P
5% H
and
0.5% P
2.5
5
10
10
IU/kg IU/kg IU/kg
IU/kg

Controls

139.9
± 12.4

144.0
± 7.8

147.5
± 4.7

168.7
± 9.9 164.0
±
29.9

136.7
± 5.1

15
IU/kg&
(Sl)
137.7
± 6.1

113.0
± 9.0

107.7
± 5.8

109.3
± 1.8

111.7
± 8.6

67.7
± 6.9

107.1
± 4.9

2.25
1.92
± 0.20 ± 0.36

1.67
± 0.17

1.92
± 0.25

1.75
± 0.25

1.83
± 0.44

9.4
± 2.4

24.8*
± 2.7

26.7*
± 0.6

31.5*
± 4.1

50.1
± 5.5

23.34*
± 1.22

-

-

30.42
± 6.76
10
±0
0.16
± 0.0

6.28
± 3.26
37.5
±7
0.56
± 0.09

3.6
5.88
± 0.9
± 1.75
60
90
±0
±0
MRTlast
1.10
1.33
(h)
± 0.21 ± 0.18
&
H-HPβCD; P-Poloxamer 188; Insulin only

Saline Subcutaneous
(Sl) (1IU/kg)

155.0
±
32.0
1.33
±
0.17
9.5
± 3.3

-

*p < 0.05 as compared to saline using t- test;
Cnadir, minimum glucose concentration; Tnadir, time to Cnadir; Cmax, maximum insulin
concentration; Tmax, time to Cmax; MRTlast, mean residence time
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Table 6: Effect of concentration of PVA on thickness, drug loading, and disintegration
time of sublingual insulin film formulations. (data represent mean ± SD, n=6)
Formulation PVA Insulin Thickness
Drug
Disintegration
code
(mg/ml)
loading
time
(%)
(µm)
(%)
(s)
A1

25^

0.5

-

-

-

A2

30

0.5

82 ± 13

102.8 ±
10.6

74 ± 5

A3

35

0.5

85 ± 15

95.4 ± 1.7

75 ± 14

^ Film could not be peeled off easily due to less viscosity as compared to A2
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Table 7: Effect of concentration of insulin on thickness, drug loading, and disintegration
time of sublingual insulin film formulations. (data represent mean ± SD, n=6)

Formulation
code

PVA Insulin Thickness
(%) (mg/ml)
(µm)

Drug
loading

Disintegration
time

(%)

(s)

B1

30

0.25

88 ± 8

102.6 ± 18.6

65 ± 9

B2

30

0.5

82 ± 13

102.8 ± 10.6

74 ± 5

B3

30

1.0

80 ± 10

100.9 ± 14.5

63 ± 9
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Table 8: Effect of concentration of plasticizer on thickness, drug loading, and
disintegration time of sublingual insulin film formulations. (data represent mean ± SD,
n=6)

Formulation PVA Insulin
Type of Thickness Drug Disintegration
code
(mg/ml)
loading
time
(%)
Plasticizer
(µm)
(%)
(s)
(5% i.e.,
16.67% of
PVA)
C1

30

0.5

Glycerin

85 ± 11

86.5 ±
9.4

74 ± 7

C2

30

0.5

PEG 400

90 ± 15

98.6 ±
10.0

73 ± 10

C3

30

0.5

Sorbitol

81 ± 14

106.7
± 8.0

65 ± 11
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Table 9: Effect of concentration of plasticizer on thickness, drug loading, and
disintegration time of sublingual insulin film formulations. (data represent mean ± SD,
n=6)
Formulation Thickness
code
(µm)

Drug
loading

Disintegration
time

(%)

(s)

Remarks

C3

81 ± 14

106.7 ± 8.0

65 ± 11

-

D

92 ± 15

99.8 ± 9.9

75 ± 18

No effect of
incorporation
of permeation
enhancers

E

248 ± 9

106.0 ± 8.4

170 ± 24

10 IU of
insulin loaded
in film 2 by 2
cm size
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Table 10: Mechanical characterization of sublingual insulin film formulations (data
represent mean ± SD, n=6)

Parameter

Formulation D

Formulation E

Listerine® strips

Breaking force Fmax

25.8 ± 9.9

27.2 ± 4.8

24.8 ± 1.2

Tensile strength
(N/mm2)

0.051 ± 0.019

0.054 ± 0.009

0.049 ± 0.002

Young’s modulus

0.41 ± 0.16

0.71 ± 0.13

134.66 ± 9.59

12.35 ± 0.09

4.8 ± 0.7

0.037 ± 0.002

(N)

(N/mm2)
Elongation
(%)
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Figures

Figure 1: Schematic representation of the human sublingual mucosa. Adapted from (1)
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Figure 2. Standard plot of insulin assayed by HPLC method.
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Figure 3: Effect of concentration (0, 2.5, 5, and 10%, respectively) of HPβCD on the
permeation of insulin (10 IU/mL) across cellulose acetate membrane (data represent
mean ± SD, n = 3)
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Figure 4: Effect of concentration (0, 0.25, 0.5, and 1%, respectively) of poloxamer 188 on
the permeation of insulin (10 IU/mL) across cellulose acetate membrane (data represent
mean ± SD, n = 3)
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Figure 5: Comparison of in vitro permeation profiles of insulin only (10IU/mL) and along
with 5% HPβCD and 0.5% poloxamer 188 across MatTek tissue model (data represent
mean ± SD, n = 2)
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Figure 6: Comparison of in vitro permeation profiles of FITC-insulin only (10 IU/mL)
and along with 5% HPβCD and 0.5% poloxamer 188 across MDCK cell line (data
represent mean ± SD, n = 3)
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Figure 7: Comparison of in vitro permeation profiles of insulin only (10 IU/mL) and
along with 5% HPβCD and 0.5% poloxamer 188 across rat esophagus (n = 1)
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Figure 8: Effect of HPβCD (5%), poloxamer 188 (0.5%), and their combination,
respectively, on the permeation of insulin (10 IU/mL) across porcine esophagus (data
represent mean ± SD, n = 3)
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Figure 9: Comparison of in vitro permeation profiles of insulin only (10IU/mL) and along
with 5% HPβCD and 0.5% poloxamer 188 across porcine esophagus (data represent
mean ± SD, n = 3)
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Figure 10: Effect of concentration (5, 10, and 15 IU/mL, respectively) of insulin along
with 5% HPβCD and 0.5% poloxamer 188 on the permeation across porcine esophagus
(data represent mean ± SD, n = 3)
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Figure 11: Comparison of mean blood glucose profiles following administrations of
sublingual saline, sublingual insulin formulations (with combination of 5% HPβCD and
0.5% poloxamer 188) at dose of 5, 10, 15 IU/kg, respectively, and subcutaneous (SC) of
insulin only at dose of 1 IU/kg (data represent mean ± SEM, n = 3-6).
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Figure 12: Comparison of mean serum insulin profiles following administrations of A)
sublingual saline, sublingual insulin formulations (with combination of 5% HPβCD and
0.5% poloxamer 188) at dose of 5, 10, 15 IU/kg, respectively, and subcutaneous (SC) of
insulin only at dose of 1 IU/kg (data represent mean ± SEM, n = 3-6).
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Figure 13: Comparison of mean blood glucose profiles following administrations of
sublingual insulin formulations (with combination of 5% HPβCD and 0.5% poloxamer
188) at dose of 0 and 15 IU/kg, respectively, and 15 IU/kg insulin only to SpragueDawley rats (data represent mean ± SEM, n = 3-6).
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Figure 14: Comparison of mean serum insulin profiles following administrations of
sublingual insulin formulations (with combination of 5% HPβCD and 0.5% poloxamer
188) at dose of 0 and 15 IU/kg, respectively, and 15 IU/kg insulin only to SpragueDawley rats (data represent mean ± SEM, n = 3-6).
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Figure 15: Contour plot showing effect of X2 and X3 on Y at A) 5 B) 10 and C) 15
IU/mL of X1 X1: concentration of insulin, X2: concentration of HPβCD, X3:
concentration of poloxamer 188; Y: cumulative insulin permeated at 60 minutes
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Figure 16: Interaction plot showing effect of concentration of HPβCD (X2) and
poloxamer 188 (X3) on cumulative amount permeated at 60 minutes (Y) at 10 and IU/mL
of insulin (X1)
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Figure 17: Interaction plot showing effect of concentration of insulin (X1) and HPβCD
(X2) on cumulative amount permeated at 60 minutes (Y) at 0.5 % of poloxamer 188 (X3)
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Figure 18: Comparison of mean blood glucose profiles following administrations of
sublingual saline and insulin solutions at dose of 10 IU/kg along with 5% HPβCD and
0.5% of poloxamer 188, and 10 IU/kg along with 10% HPβCD and 0.3% of poloxamer
188, respectively, as well as subcutaneous (SC) of insulin at dose of 1 IU/kg to SpragueDawley rats (data represent mean ± SEM, n = 3).
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Figure 19: Comparison of mean serum insulin profiles following administrations of
sublingual saline and insulin solutions at dose of 10 IU/kg along with 5% HPβCD and
0.5% of poloxamer 188, and 10 IU/kg along with 10% HPβCD and 0.3% of poloxamer
188, respectively, as well as subcutaneous (SC) of insulin at dose of 1 IU/kg to SpragueDawley rats (data represent mean ± SEM, n = 3).
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Figure 20: Comparison of mean blood glucose profiles following administrations insulin
solutions at dose of 2.5, 5, and 10 IU/kg, respectively, along with 10% HPβCD and 0.3%
of poloxamer 188 to Sprague-Dawley rats (data represent mean ± SEM, n = 3).
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Figure 21: Light micrographs of the porcine esophagus following in vitro permeation
study for A) formulation containing insulin (10 IU/mL) along with HPβCD (5%) and
poloxamer 188 (0.5%) B) formulation containing insulin (10 IU/mL) along with HPβCD
(10%) and poloxamer 188 (0.3%) and C) control, PBS
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Figure 22: Stress-strain curves for A) formulation E and B) Listerine®
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Figure 23: In vitro dissolution for formulation E in PBS, pH 6.8 and simulated saliva.
(data represent mean ± SD, n = 3)
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Figure 24: Comparison of in vitro permeation profiles of insulin solution (10 IU) along
with 5% HPβCD and 0.5% of poloxamer 188 and formulation E (10 IU) across artificial
membrane (data represent mean ± SD, n = 3)
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Figure 25: Percentage of insulin remained in sublingual insulin film dosage form stored
at room temperature (25 ± 2°C ) and in the refrigerator (2-8 °C) (data represent mean ±
SD, n = 3)
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